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SINE OCULIS HOMEOBOX HOMOLOG 1 (SIX1) PLAYS A CRITICAL ROLE
IN THE PROGRESSION OF PULMONARY FIBROSIS.
Cory Miles Wilson
Advisory Professor: Harry Karmouty-Quintana Ph.D.
Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial
pneumonia with a median survival time of 2-4 years after diagnosis. The alarming
mortality rate is due to the lack of effective treatments. IPF is a chronic disease that is
characterized by alveolar destruction due to increasing extracellular matrix deposition
that leads to poor lung compliance, impaired gas exchange, and ultimately respiratory
failure. Repetitive alveolar epithelial injury is a central process to the underlying
pathology with injury to the type II alveolar epithelial cells (AT2) specifically being a
key player in the pathogenesis of IPF. Recent studies have shown that recapitulation of
developmental genes in AT2 cells is associated with the abnormal epithelial phenotype
seen in IPF, however the specific genes and the mechanisms of how they alter
epithelial function are poorly understood. The work in this dissertation addresses one
such developmental gene, Sine Oculis Homeobox Homolog 1 (Six1), which is a
transcription factor that is essential for normal lung morphogenesis in utero that I
show to be inappropriately expressed in the AT2 cells in IPF.
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Dissertation Overview
Rationale
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial
pneumonia. IPF is a particularly deadly disorder affecting approximately 8 million
people worldwide with a median survival time of 2-4 years after diagnosis. Despite its
prevalence and current knowledge of genetic risk factors, there is a lack of knowledge
about the mechanisms governing its progression. IPF is a chronic disease that affects
the most distal portion of the lung that is responsible for normal breathing and gas
exchange termed the alveoli. IPF is characterized by alveolar destruction due to
increasing extracellular matrix deposition that leads to poor lung compliance,
impaired gas exchange, and ultimately respiratory failure. Repetitive alveolar epithelial
injury is a central process to the underlying pathology with injury to the type II
alveolar epithelial cells (AT2) specifically being a key player in the pathogenesis of IPF.
Recently, studies have shown that recapitulation of developmental genes in
alveolar epithelium, specifically the AT2 cells, is associated with the abnormal
epithelial phenotype seen in IPF. Some previously studied developmental pathways
are the Sonic hedgehog (Shh), wingless/integrase-1 (Wnt), Notch, and Bone
morphogenetic protein (BMP) pathways. The Shh and Wnt pathways have shown to
be reactivated in AT2 cells and result in increased proliferation, differentiation,
collagen production and decreased apoptosis of the surrounding lung fibroblasts,
however the mechanisms of how they alter AT2 epithelial cell function are still poorly
understood.
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I used this rationale of developmental gene expression in IPF to perform a DNA
microarray screen of developmental gene mRNA expression in human lung samples of
IPF patients. The screen consistently showed increased expression in IPF samples of
the developmental gene Sine Oculis Homeobox Homolog 1 (Six1). This project was
further identified by additional supporting data including increased Six1 mRNA and
protein expression levels in lung explants of IPF patients, as well as in experimental
mouse models of lung fibrosis. Using this foundational data and the lack of studies
looking at Six1 in lung fibrosis, I designed this thesis that explores Six1 and the role of
Six1 in AT2 cells in the context of lung fibrosis.

Background
The Six family is composed of genes Six1-6, all of which are expressed in both
mice and humans, and are characterized by the conserved protein interacting Six
domain (SD; 110-115 amino acids) and the DNA-binding homeobox domain (HD; 60
amino acids). Six1 is an essential transcription factor for normal lung morphogenesis
in utero and is normally not expressed in most adult tissues. Absence of Six1 in mice
leads to severe epithelial branching abnormalities and pulmonary hypoplasia,
underscoring the vital role Six1 plays in normal lung development. In contrast, various
adult pathologies demonstrate inappropriately increased Six1 expression in adult
tissues, including breast, esophageal, and lung cancers. Mechanistically, Six1 is known
to contribute to tumor formation and metastatic progression by regulating multiple
activities of cancer cells such as responsiveness to apoptotic stimuli, cell proliferation,
and epithelial differentiation, including through activation of transforming growth
2

factor (TGF)-β signaling. In lung development, Six1, in a complex with transcriptional
co-regulator Eya1, was shown to directly modulate the expression and targeting effects
of the sonic hedgehog (Shh) pathway and AT2 cell markers, surfactant proteins B and
C. Despite this understanding and increased research of Six1 in cancer and
development, there are currently no studies looking at Six1 in pulmonary fibrosis.

Central Hypothesis
This project investigates the hypothesis that Six1 expression in the AT2 cells
drives the progression of lung fibrosis through the modulation of the proliferative and
pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF).
I built upon this hypothesis and demonstrated that there is increased Six1
transcript and protein expression in IPF compared to healthy controls. I also
demonstrate that conditional deletion or overexpression of Six1 in AT2 cells in mice
can significantly halt or worsen development of lung fibrosis, respectively. I also
propose a novel mechanism whereby Six1 modulates MIF expression in AT2 cells that
is important for the progression of lung fibrosis. The following aims outline the details
of this project.
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Specific Aims
Specific Aim 1: Determine the role of Six1 expression in the development of
pulmonary fibrosis.
Six1 is critical for proper development of the lungs and multiple other organs.
However, Six1 itself lacks an activation domain, requiring a binding partner to affect
transcription of downstream target genes. Eyes absent (Eya) is a family of known
transcriptional co-regulators of Six1. Eya1 and Eya2 play an activating role when in
complex with Six1. The Six1/Eya1 complex has shown to play a role in cancer metastasis
and cancer cell proliferation. Using IPF patient samples and healthy controls, Six1 and
both of these known transcriptional co-activators Eya1 and Eya2 were measured by
RT-qPCR, immunohistochemical staining, and western blotting showing increased
levels in IPF lung samples. These data were recapitulated in vivo using two distinct
mouse models of lung fibrosis including the intraperitoneal (IP) bleomycin (BLM)
mouse model and the spontaneous, telomere shortening Trf1-/- model to demonstrate
the expression of Six1, Eya1, and Eya2 in both experimental models of lung fibrosis.
Subsequently, Six1, Eya1 and Eya2 expression was localized to the AT2 cell in IPF and
both mouse models using RNA in situ hybridization, immunohistochemical staining,
and RT-qPCR. The demonstration of increased Six1 along with both Eya1 and Eya2
demonstrates that Six1 is in the presence of known coactivators needed to actively
modulate transcription of target genes. These data were used as rationale for the
generation of an AT2-specific Six1 conditional knockout mouse model, the Six1f/f SPCCreERT2 mice, in order to study the role of Six1 in AT2 cells. This model was then used
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to show that depletion of Six1 protected mice from development of lung fibrosis. The
details of this aim are summarized in chapter 3.

Specific Aim 2: Evaluate the role of Six1 in the lung alveolar epithelial type II
cells.
In IPF patient lung samples it was shown that Six1 expression was localized to
the AT2 cells and that depletion of Six1 from the AT2 cells protected mice from the
development of pulmonary fibrosis however what effects Six1 had on the AT2 cells or
if it was causative was unknown. Using this rationale I generated an additional
conditional Six1 overexpressing mouse model, the Six1TET SPC-rtTA mice, which
demonstrated that over-expression of Six1 in the AT2 cells led to increased mortality
and a worsened fibrotic phenotype, including worsened lung function, histological
fibrotic deposition, and increased collagen production. In vitro RNA-seq analysis of
Six1 using an MLE-12 mouse alveolar type II cell line show that Six1 increases the
transcript and protein level of the profibrotic cytokine macrophage migration
inhibitory factor (MIF). MIF is a proinflammatory and profibrotic cytokine that is
increased in several chronic lung diseases including IPF, however how MIF is
regulated and its role in IPF is not fully understood. These results were recapitulated
in vivo using the intraperitoneal BLM mouse model with the Six1f/f SPC-CreERT2 and
Six1TET SPC-rtTA mice that showed increased transcript levels of MIF as well as
increased secreted MIF protein. It was then demonstrated that MIF increases the
proliferation and differentiation of primary human lung fibroblasts. Collectively, I
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propose a unique mechanism for the novel Six1/MIF signaling axis. The details of this
aim are summarized in chapter 4.
Specific Aim 3: Determine the therapeutic potential of targeting Six1 in
established pulmonary fibrosis.
Assessing novel therapies for IPF is a daunting task. This disease is
multifactorial and potentially has many escape mechanisms and a highly variable
clinical course. Recently, in 2014 two drugs were FDA-approved for the treatment of
IPF, however these are non-curative and do not significantly decrease overall
mortality. The paucity of current treatments for patients with IPF necessitates the
development of novel treatment strategies. The majority of studies of lung fibrosis
that use pre-clinical animal models have focused on the prevention of lung fibrosis by
treating the animals prophylactically with very few studies looking at therapeutic
capacity in already developed lung fibrosis. Therefore, I aimed to test the therapeutic
capacity of targeting Six1 using the Six1f/f SPC-CreERT2 mice to conditionally delete
Six1 during the development of fibrosis at Day15 of BLM treatment and after the
development of fibrosis at day 33. Therapeutic targeting of Six1 resulted in decreased
fibrosis and significantly improved lung function. The details of this aim are
summarized in chapter 5.

Scientific Significance
The incidence of IPF in North America is approximately 18 cases per 100,000
people each year, with no curative medical treatment available. High mortality rates
and limited treatment options underscore the importance of elucidating the
6

underlying mechanisms in IPF, potentially leading to the development of novel
therapies for this fatal disease. This project explicitly investigates the role of Six1 in
AT2 cells in the setting of pulmonary fibrosis and adds to the current scientific
understanding of IPF by addressing two innovative concepts: 1) Identification of the
transcription factor Six1 in AT2 cells in IPF and 2) Proposal of a molecular mechanism
for Six1 in AT2 cells with the experimental evaluation of Six1 as a potential treatment
strategy for established lung fibrosis. The completion of the aims outlined help
advance the mechanistic understanding of pulmonary fibrosis by identifying a unique
role for the transcription factor Six1. Understanding the mechanisms by which Six1
acts on the AT2 cells will be key to the development of novel therapeutic targets and
the advancement of the current scientific understanding of the progression of
pulmonary fibrosis and provides unique opportunities on which to build future
research.
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Chapter 1: Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Epidemiology
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial
pneumonia (1). It is a chronic, progressive disease characterized by alveolar
destruction with increased extracellular matrix (ECM) deposition, leading to poor lung
compliance, impaired gas exchange, and, ultimately, respiratory failure (2-5). IPF is
observed in predominately older males 60-70 years old with cases of IPF occurring
rarely in patients under 50 (6). The incidence of IPF in North America and across the
world has been elusive due to the complexity of clinical interpretation and nonuniform disease definition that has led to seemingly conflicting reports (2, 7). Recently
in the United States, Medicare data from 2001-2011 was analyzed showing the
incidence of IPF in the US to range from 15.9 – 31.1 cases per 100,000 per year using a
narrowed, more specific definition of the disease. Incidence of IPF worldwide is now
estimated to be lower at 3 – 9 cases per 100,000 per year with a current overall
prevalence of 8 million affected individuals (1, 7). Overall, the incidence and
prevalence increases with age and is a problem that is continuing to rise, underscoring
the importance of continued research into the pathogenesis and novel treatment
strategies to combat this problem.
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Diagnosis & Clinical Description
The diagnosis of IPF is a complex and often multi-factorial disease that
requires interpretation of complex imaging and clinical evaluations from across
multiple medical specialties (2). The challenges in diagnosis have stemmed from the
lack of a consensus definition when developing large clinical trials and often
conflicting expert opinion. In 2011, this problem was addressed by Raghu et al. (6)
when the authors described specific clinical criteria for IPF. This definition has been
used to provide well-characterized parameters for inclusion and, more importantly,
exclusion criteria for large clinical trials that have allowed for the appropriate
selection of patients. Since the 2011 criteria, large cohorts of well-defined patients have
provided the field with new clinical insights about disease presentation and
progression of the disease (8, 9). These trials have improved the clinical knowledge of
the disease that has allowed for the most current description of IPF to be described by
Lynch et al. in 2018 (2). IPF belongs to a subset of diffuse parenchymal lung diseases
(DPLD) known as idiopathic interstitial pneumonias (IIP). It is important to exclude
alternative diagnoses when defining IPF since there are potentially treatable
conditions with similar clinical presentations including connective tissue disease
(CTD) and hypersensitivity pneumonitis (HP) (2). The foundation of an accurate IPF
diagnosis relies on critical interpretation of CT (computed tomography) imaging. The
most important key characteristic that is used to define IPF on chest CT images is
honeycombing. The presence of honeycombing on imaging is critical for diagnosis as
well as prognosis of the patient (10, 11). Honeycombing is defined as clustered, thickwalled cystic spaces measuring between 3-5 mm located generally, in the basal and
9

sub-pleural regions of the lung (12). The addition of course, irregular reticulations with
the presence of traction bronchiectasis (bronchiolar dilatation) and basal-predominate
honeycombing is the radiological definition of UIP (usual interstitial pneumonia).
Patients are placed into four diagnostic categories based on high-resolution chest CT:
UIP/IPF, probable UIP, indeterminate UIP, and alternative diagnosis (13). In the case
of probable UIP and indeterminate UIP it is currently recommended to correlate with
the histopathological pattern of UIP showing marked subplueral fibrosis with
parenchymal involvement and fibrobalstic foci on surgical lung biopsy (13). Clinically,
an IPF patient will present with a history of progressive, dry cough and dyspnea on
exertion with the physical exam findings of digital clubbing with bibasilar inspiratory
crackles (1, 6, 14).

Risk Factors & Biomarkers of IPF
Although IPF is idiopathic, several well-studied risk factors, such as sex,
smoking, and age increase the risk of developing IPF. There are a higher prevalence of
men affected compared to women (2:1) with a strong smoking history (~20 pack years)
being one of the most important environmental risk factors (15). However, there are
other factors that have been associated including wood and metal particulate matter,
silica dust, and certain viruses (1, 14). Several co-morbidities associated with IPF
include gastro-esophageal reflux (GERD), obstructive sleep apnea (OSA), and obesity
(14). Optimized management of these co-morbid conditions could prove to be useful
tools to modulate the course or progression of the disease.
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Genetic markers for IPF have also been discovered, including mutations in the
mucin 5B MUC5B gene, which codes an essential protein for airway clearance and
innate immune response. It was shown that a single-nucleotide polymorphism (SNP)
rs35705950 located approximately 3 kilobases upstream of the transcription start site
(TSS) in the MUC5B promoter was associated with both sporadic IPF and familial
interstitial fibrosis (16). This one genetic risk factor accounts for a defined risk for 38%
of patients with IPF and 34% of familial cases of interstitial lung disease (14-16). In
2017, a study that included 2760 IPF patients also identified a SNP variant near Akinase anchoring protein 13 (AKAP13; rs62025270) as a susceptibility factor for the
development of IPF (17). Telomere biology has led to advancements in understanding
more about DNA maintenance and cell survival in the past two decades. As such, in
2007 Arminios et al. described a link between families with familial pulmonary fibrosis
associated with the rare genetic disease dyskeratosis congenita (18). This was followed
by subsequent research that aimed to test the hypothesis that IPF was caused by
shortened telomeres and increased DNA damage that showed additional genetic
mutations in the genes associated with the telomerase enzyme, telomerase RNA
component (TERC) and telomerase reverse transcriptase (18-21). This is further
supported by four genes, Dyskeratosis Congenita 1 (DKC1), Regulator Of Telomere
Elongation Helicase 1 (RETL1), TERF1 Interacting Nuclear Factor 2 (TINF2), Poly(A)Specific Ribonuclease (PARN), that are associated with familial pulmonary fibrosis
accounting for the increased risk of developing pulmonary fibrosis, including IPF, in
approximately 8-24% of patients (22-24). Mutations in the critical surfactant protein
(SFTP) genes, important for reduction of surface tension and innate immunity, SFTPC,
11

SFTPA2, and SFTPD have been associated with families and individuals with IPF.
Recently, in a large meta-analysis of the Prospective Study of Fibrosis In the Lung
Endpoints (PROFILE) cohort showed a strong correlation with overall mortality and
disease progression with patients with higher SFTPD plasma levels (25, 26).
Due to the insidious onset and rapid progression of IPF post-diagnosis, there
has been an increased need for more accurate and predictive markers to aid in the
clinical diagnosis and prognosis of IPF. Briefly, I discuss some potential serum and
bronchoalveolar lavage fluid (BALF) biomarkers that are emerging. The link between
cancer and IPF has been postulated due to similar destruction of the surrounding
tissue and hyperproliferative response. The oncomarkers CA125, CA15-3, CA19-9, and
CEA are all shown to be increased in the plasma of IPF patients with CA-15-3 positively
correlating to poor prognosis. Interestingly, in IPF patients that received lung
transplants the biomarkers CA125, CA15-3, and CA19-9 all decreased post-transplant
(27, 28). Studies have also shown the markers C-proSFTPB, αvβ6 integrin, and
autoantibodies to heat shock protein- 70 (HSP-70) to correlate with poor outcomes
and more acute exacerbations in IPF patients (29-31).

Treatment
In discussing treatment strategies for IPF it is important to address both nonpharmacological and pharmacological options and how they affect the prognosis of
disease. In a disease like IPF with few options, non-pharmacological interventions
help patients optimize their condition and improve quality of life. The first
component of treatment to consider in IPF is oxygen supplementation. Current
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guidelines recommend supplemental oxygen for all patients with an oxyhemoglobin
saturation of 88% or less either at rest or with exertion (4, 6). Other options include
pulmonary rehabilitation, which can improve quality of life and decrease acute
exacerbations, and optimization of co-morbid conditions such as obesity,
hypertension, and diabetes (4). Currently, there remains only one curative, nonpharmacologic therapeutic option for patients with advanced disease: lung
transplantation.
Lung transplantation has evolved dramatically since the first lung transplant
case for IPF in 1983 (32). It is still the best option for improving overall survival, lung
function, and quality of life. However, lung transplant is not devoid of risk and carries
a high overall mortality rate. Recent analysis from lung transplant data from the
Scientific Registry of Transplant Recipients (SRTR) from January 2007 to May 2017
showed that post-operative mortality of IPF patients (ICD10-1604) that underwent a
single lung transplant (SLT) had 88.2%, 55.2%, and 25.7% 1, 5, and 10 year overall
survival rates, respectively (33). This is a higher overall mortality compared to other
solid organ transplants (SOT) reported by the SRTR including liver with 1- and 5-year
survival of 91.2% and 75%, respectively, and kidney with 1- and 5-year survival rates of
97.5% and 85.6%, respectively (34). Assessing if a patient with IPF should undergo
lung transplant is a multidisciplinary decision and is one that has seen improvement
in recent years. Now, there are several predictors of outcome that are widely used
including forced vital capacity (FVC) and chest CT gender-age-physiology (GAP)
score, both of which are good predictors of overall outcome for patients (35, 36). In
addition is how transplant donor lungs are allocated to patients based on predictive
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value of outcome. The lung allocation score (LAS) is used to predict where on the
transplant list a patient will be and what level of priority they receive and who will
benefit the most from a transplant. Under the LAS system, lung transplants in the US
due to IPF have increased from 21% to 32% with better predictive response and less
wait time (37).

Overall lung transplant outcomes are improving and are the

cornerstone of non-pharmacological therapy for IPF.
For many years, it was believed that IPF was a condition secondary solely to
uncontrolled inflammation. The treatment thus was limited to only chronic
corticosteroids or another immunomodulatory agent, which proved to provide little
clinical benefit and was associated with several long-term side effects for the patients
(6, 15). To this end, pulmonologists would treat their patients with a 2-drug
combination therapy of prednisone and azathioprine, an immunosuppressive drug, or
a 3-drug regimen with the previous two drugs plus N-acetylcysteine (NAC) with
anecdotal evidence of improvement among IPF patients. The most notable shift in
research into therapies and advancements in clinical guidelines came following a
randomized, placebo-controlled trial aimed at showing the benefit of this common 3drug regimen called the Prednisone, Azathioprine, and N-Acetylcysteine: A Study
That Evaluates Response in Idiopathic Pulmonary Fibrosis (PANTHER-IPF;
NCT00650091) (38). This trial was an important turning point for the pulmonary field
as it not only showed no significant clinical improvement, but instead showed both
significant increased rate of death (8 vs 1) and hospitalization (23 vs 7). This data was
used to terminate the trial early at week 32 instead of the original 52-week planned
study (38).
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Since the PANTHER-IPF trial, there were several trials that focused on more
specific disease processes in IPF that ultimately led to two FDA-approved
pharmacological therapies. The first treatment to be studied at length was Pirfenidone
(Esbriet) (5-methyl-1-phenyl-2-[1H]-pyridone) due to its ability to regulate the
profibrotic mediator TGF-β in vitro (39, 40). Two large multinational randomized,
double blind placebo-controlled trials (RCT) were used to assess Pirfenidone as an
anti-fibrotic drug, CAPACITY 004 (NCT00287729) and CAPCITY 006 (NCT00287716).
The CAPACITY (Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary
Fibrosis) 004 trial showed a mean FVC change of 4.4% from an average of -12.4% in
the placebo group to -8.0% in the treatment group (41). However, the CAPACITY 006
trial showed no statistical improvement in the primary endpoints. A third Phase III
trial was then performed, the Assessment of Pirfenidone to Confirm Efficacy and
Safety in Idiopathic Pulmonary Fibrosis (ASCEND; NCT01366209) study. This study
showed significant improvement in decline in lung function by approximately 48%,
less decline in 6-minute walk test (6MWT), and progression-free survival that
prompted the FDA to approve Pirfenidone in October 2014 (42).
The second drug to be extensively researched was the tyrosine kinase inhibitor
Nintedanib (Ofev). Nintedanib inhibits vascular endothelial growth factor receptor
(VEGFR), fibroblast growth factor receptor (FGFR), as well as platelet- derived growth
factor receptor (PDGFR) (43). There were 3 large, Phase II/III double-blind placebo
controlled trials conducted from 2011-2014 assessing the use of Nintedanib in patients
with IPF. The phase II trial named, To Improve Pulmonary Fibrosis with BIBF 1120
(TOMORROW; NCT00514683) was a dose finding trial that reported a significant
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difference in their primary endpoint of less decline in FVC over 52 weeks. The next
two Phase III trials named Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic
Pulmonary

Fibrosis

Patients

(INPULSIS-1;

NCT01335464)

and

(INPULSIS-2;

NCT01335477) were designed in similar fashion to the CAPACITY trials and assessed
FVC decline over 52 weeks as their primary endpoint (44). Nintedanib showed a
significant improvement (-112.4 mL vs -223 mL) in decline in FVC compared to placebo
(44). This led to the rapid FDA approval of Nintedanib to treat IPF patients in October
2014. Recently in 2019, Nintedanib was FDA approved for pulmonary fibrosis related to
systemic sclerosis (SSc-ILD) based on the conclusion of the trial for Safety and Efficacy
of Nintedanib in Systemic Sclerosis (SENSCIS; NCT02592933) showing less decline (52.4 mL vs -93.3 mL) in FVC over 52 weeks (45).
Patients with pulmonary fibrosis, including IPF or other fibrosing interstitial
lung disease (ILD), can have two different clinical courses; a slow, steady decline or a
rapidly progressive decline in lung function. This rapidly progressive group termed
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) is defined as a person with
>10% fibrotic burden on chest CT imaging with continual decline in lung function,
dyspnea, and quality of life with a poor or no response to current pharmacological
therapy (46). In March 2020, Nintedanib was FDA approved for this subgroup of
patients with PF-ILD after the conclusion of the Efficacy and Safety of Nintedanib in
Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) trial (INBUILD;
NCT02999178) (47). These recent advancements in IPF and subgroups of fibrosing ILD
treatment have reshaped the clinical management of lung fibrosis patients over the
last 5 years.
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Currently the field is exploring several new options for therapy for IPF
including 20 active Phase II/III clinical trials in the US. Two of the most promising
new studies are looking at targeting connective tissue growth factor (CTGF) and
autotaxin (ATX) (48, 49). Both of these molecules have been implicated in the
aberrant wound healing response that is perpetuated in IPF patients. The Phase II
PRAISE trial (NCT01890265) studied the efficacy of pamrevlumab (FG-3019) the
human monoclonal anti-CTGF antibody that showed a reduction in FVC by 60.3% in
IPF patients(48). This study is now a Phase III clinical trial. Currently, two large,
identical Phase III trials, the Clinical Study to Test How Effective and Safe GLPG1690
is for Subjects With Idiopathic Pulmonary Fibrosis (IPF), (ISABELA-1; NCT03733444
and ISABELA-2; NCT03711162) are looking at a novel ATX inhibitor GLPG1690. ATX is
an enzyme responsible for the production of lysophosphatidic acid (LPA), which has
been implicated in IPF progression (49).
Over the last 10 years the research for IPF treatment has evolved and is focused
on more specific mechanisms of disease, however, there is still a large gap in
knowledge and only 2 FDA approved therapies for patients facing a disease with a very
poor prognosis.

Disease Mechanisms
Historically, IPF was considered a disease of progressive and uncontrolled
inflammation that eventually led to insidiously progressive sub-pleural fibrosis (14).
After the conclusion of the PANTHER-IPF trial, it was substantiated that IPF involves
many more complex molecular determinants of disease than solely inflammation.
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Recently, new insights into the pathophysiology of IPF advance the idea that repetitive
alveolar epithelial injury is a central process contributing to fibrosis development.
Injury to the alveolar progenitor cells, type II alveolar epithelial cells (AT2), has been
proposed to be central to IPF pathogenesis(1, 50, 51). IPF is considered a multifaceted
process with the following alterations in lung cell biology: chronic inflammatory and
immune activation, differentiation and modulation of fibroblasts leading to ECM
deposition modulating aberrant repair processes, and chronic injury and activation of
alveolar epithelium (1, 4, 14, 52). Herein I will elaborate on each of these fundamental
concepts and their role in IPF pathogenesis.
Inflammation
Although the exact role of how inflammation is modulating IPF development
and progression is not fully delineated, it is clear that chronic inflammation plays a
role. Studies have shown an association to increased mortality with worse prognosis
for patients with high levels of inflammation and 50-70% of IPF patients have
increased inflammatory cells in their BALF (6, 53). The pro-inflammatory environment
in the lungs of patients with IPF has been proposed to contribute in several ways to
the pathogenesis through enhanced chemotaxsis, promoting impaired wound healing,
extracellular matrix (ECM) remodeling, increased oxidative stress, and activation of
fibroblasts (54). Inflammation has also been recapitulated in several animal models of
pulmonary fibrosis that show robust increases in macrophages, lymphocytes and
neutrophils in the lungs and BALF in these mouse models (55). The chronic
inflammatory pathway causes abnormal immune activation and contributes to lung
fibrosis, but IPF has been recently redefined as a specific interstitial lung disease that
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is driven by an epithelial-dependent fibroblast activation with a poor response to antiinflammatory treatment (15). However, deregulated inflammation and sporadic
inflammatory insults could be responsible for differences in progression of IPF. This
reclassification away from solely an inflammatory disease has allowed for the
separation of two distinct potential disease pathways: the inflammation pathway and
the epithelial-fibroblast pathway. Thus, the mechanisms of aberrant epithelial
activation and fibroblast differentiation will be the focus of this thesis and discussed in
more detail.
Fibroblast activation
Briefly, the normal wound healing response consists of several stages including
homeostasis, inflammation and cell migration, proliferation and ECM remodeling, and
resolution (56). In the lung, the normal wound healing response begins with the initial
insult to the alveolar epithelium that results in the release of pro-inflammatory
cytokines such as transforming growth factor (TGF)-β and platelet-derived growth
factor (PDGF), which then attract macrophages and neutrophils. The neutrophils aid
in the clearance and degradation of extracellular debris and the macrophages help by
releasing matrix metallopeptidases (MMP) as well as promote the proliferation of
fibroblasts in order to construct a scaffold of ECM. The AT2 cells then migrate to the
newly formed ECM scaffold and trans-differentiate to new functional epithelial cells in
order to re-populate and replace the damaged epithelium (56, 57). In IPF, AT2 cells are
highly active and continue to perpetuate this normal wound healing cascade despite
the absence of the intial injury. This dysfunction of the normal wound healing
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response is central to IPF and has been the cornerstone of fibrosis research for decades
(15).
The constitutive activation of fibroblasts to myofibroblasts is one of the
hallmark events that occurs in IPF and one that attributes this deregulated would
healing response to the pathogenesis of IPF. This chronic activation of fibroblasts and
the corresponding development of fibrosis is marked by the expression of the protein
alpha-smooth muscle actin (aSMA) which is a marker of the highly contractile and
ECM producing myofibroblasts. Myofibroblasts express several ECM proteins
including laminin, collagen, and fibronectin. The most widely studied signal for the
development of myofibroblasts is the TGF-β superfamily of growth factors (58). The
TGF-β superfamily includes 33 known proteins which include TGF-β1, 2, and 3 and
bone morphogenetic proteins (BMP). In lung fibrosis, the TGF-β1 isoform has been
shown to be most critical in the development of myofibroblasts(59). TGF-β1 signals
through the extracellular binding to the transforming growth factor receptor II
(TGFBRII)

followed

by

the

dimerization

with

TGFBR1

and

subsequent

phosphorylation of the Smad proteins 2 and 3 which are then transported by Smad4
into the nucleus where they then activate other transcription factors to modulate
TGF-β target genes (58, 59). De novo expression of aSMA in lung fibroblasts is driven
by the increase in TGF- β1 signaling through the direct binding of Smad3 to the
promoter of the ACTA2 gene (60). Additionally, TGF-β1 increases fibroblast
differentiation to myofibroblasts through inhibition of Glycogen synthase kinase 3
(GSK3β) and increase in nuclear β-catenin signaling through the activation of ERK1/2
(61). The sources of TGF-β have been shown to be primarily from macrophages and
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hypertrophic alveolar epithelial cells (59). The study of fibroblast differentiation
through TGF-β signaling has led to numerous clinical trials and one FDA-approved
drug for IPF. Alternative mechanisms for the activation and differentiation of
fibroblasts are rapidly evolving and include studies looking at wingless/integrase-1
(WNT) signaling, microRNA’s, G-protein coupled receptor signaling through
lysophosphatidic acid (LPA), fibroblast growth factors, various cytokines (e.g. CTGF),
and mechanosensitive activation through changes in ECM architecture (1, 14, 62).

Alveolar epithelial cell injury
In recent years, the chronic injury and activation of the alveolar epithelial cells
leading to a maladaptive wound repair mechanism in IPF has been an area of great
interest. Specifically, the deregulation and injury to the alveolar type II cell (AT2) is
central to IPF pathogenesis. The alveoli of the lung are comprised of alveolar type I
(AT1) and AT2 cells that together comprise the functional unit of the lung that is
responsible for gas exchange and normal respiration. AT1 cells are thin, squamous
epithelial cells that range from 0.1-0.2 micrometers (um) and comprise a semipermeable layer that allows for the rapid exchange of oxygen and carbon dioxide and
cover approximately 95% of the total surface area for gas exchange in the lung,
although by cell mass only comprise 8% of total cells in the lung (63). In contrast, AT2
cells are cuboidal epithelial cells that comprise 16% of the total cell number in the lung
but provide little to gas exchange (63). However, AT2 cells provide several critical
functions in the distal lung including surfactant production, proliferative expansion,
multipotent progenitors, and innate immunity (64). An AT2 is defined as a distally
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restricted epithelial cell with the presence of cytoplasmic, lamellated organelles with
high lipid content and the expression of the four surfactant protein (SP) genes, SPA,
SPB, SPD and SPC, with SPC being a hallmark of AT2 cells (64, 65). The definition of
an AT2 cell is of great importance in the field of IPF research in order to investigate
the full recapitulation of the AT2 cell phenotype from large, available cell sources (e.g
iPSC, hESC) for use in potential future IPF therapies (14, 64). Mechanistically, injury to
the AT2 cell is a central driver in fibrosis development and has been proposed to be
due to several metabolic, genetic and functional disturbances including cellular
senescence, oxidative stress, shortened telomeres, DNA damage, altered proteostasis,
and reactivation of developmental pathways (1, 14, 51, 65-69). For conciseness, I will
be focusing on the reactivation of developmental pathways as drivers of AT2 cell
dysfunction in IPF.
In 2008, there was a study that focused on large-scale microarray data
generated from lung biopsies from control patients and IPF and correlated it with
known published data in order to develop more insights into the underlying
mechanisms on disease(70). This revealed that there was a broad range of
developmental pathways that were aberrantly expressed in the alveolar epithelium of
IPF patients. In the last decade, this has been reproduced and is now recognized to be
a contributor of IPF pathogenesis. Two pathways that have been well defined in AT2
cells are the WNT and Shh pathways. These two pathways are important during lung
development and are shown to have some of the same embryonic functions, but have
also shown differences, in their function in adult diseases like IPF (51, 65, 71).
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Briefly, the canonical WNT signaling involves the binding of a WNT ligand
(e.g. WNT-1, WNT3a) to its Frizzled (FZD) receptor and subsequent activation of the
low-density lipoprotein receptor (LRP5/6). This then allows for an increase in free
cytoplasmic β-catenin through the inactivation of several kinases including GSK3β and
casein kinase 1 (CK1). Β-catenin is then transported to the nucleus were it acts with the
T cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to modulate
the expression of downstream WNT target genes (65). In lung development, the
canonical WNT ligands WNT7, WNT11, and WNT2 are expressed in the epithelium
(WNT7/WNT11) or mesenchymal cells (WNT2) (72-74). The expression of WNT
ligands in early (E9.0) in the psuedoglandular stage of lung development drives the
expression of the homeobox transcription factor Nkx2.1 that is important in lung bud
patterning in the developing lung and lack of β-catenin signal or through WNT
antagonism shows lung agenesis in mice (75, 76). The epithelial-specific antagonism of
WNT signaling in the developing lung leads to dysregulated branching morphogenesis
of the epithelium with inappropriate proximal to distal patterning (77, 78). In the
adult lung, the AT2 trans-differentiation to AT1 cells seen in normal wound healing is
directly related to the β-catenin driven gene expression. In normal wound healing,
WNT signals are activated then subside to low basal level, however in IPF
inappropriately elevated levels of nuclear β-catenin in AT2 cells drives transdifferentiation and increase in migration of AT2 cells (65). This was demonstrated by
the overexpression of the endogenous β-catenin antagonist DKK1 and use of β-catenin
siRNA to show decrease in migration and lower levels of AT1 generation in vitro in
primary human cell culture (79). This is thought to lead to the loss of functional AT2
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cells to proliferate and repopulate the epithelium after long term epithelial damage
induced in IPF leading to the deregulated and dysfunctional wound repair response.
Recently, this previously elucidated role of WNT signaling has been complicated by
several studies that show conflicting roles in alveolar epithelium. AT2 specific deletion
of β-catenin showed a deleterious effect in BLM induced fibrosis in mouse models
with decreased AT2 cell proliferation, which is in contrast to the previously discussed
pathogenic role of WNT in IPF (80). This was supported by recent work that described
a subset of AT2 cells referred to as alveolar epithelial progenitor cells (AEP) that are
WNT-responsive, Axin2+, SPC+ cells that comprise approximately 20% of the bulk
AT2 cells in the adult lung (81). These cells are responsible for the multipotent
function of AT2 cells and the trans-differentiation of AT2 to AT1 is driven in these cells
by the loss of WNT/ β-catenin signaling. In support of the AEP role in maintaining a
progenitor pool in the distal lung, it was shown that local fibroblast-AT2 niche where
a resident fibroblast maintains an AEP in an AT2 like state through the local activation
of WNT signaling in the AEP. Upon injury, the AEP then migrates to the wound as in
normal wound healing response and as it migrates further from the active WNTsecreting fibroblast, it undergoes AT2-AT1 transition due to lack of WNT signal (82).
The evolving role of epithelial WNT signaling in IPF provides substantial evidence that
the reactivation of developmental genes can play critical roles in the progression of
disease with contrasting roles compared to lung development.
The hedgehog pathway also provides insight into the role of developmental
genes in IPF pathogenesis. Briefly, in mammalian canonical hedgehog (HH) signaling,
one of the three HH ligands, either Indian (Ihh), Desert (Dhh), or Sonic (Shh) binds to
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its receptor Patched-1 (PTCH1) or Patched-2 (PTCH2), removing PTCH inhibition of
smoothened (83). When inhibition is removed, the activator forms of the GliomaAssociated Oncogene Homolog (GLI) transcription factors, GLI1, 2, or 3, increase
expression of downstream target genes (84). During normal lung embryogenesis, Shh
signaling regulates distal epithelial cell branching morphogenesis at days E10.0 to 16.5
and mesenchymal proliferation starting at day E11.5 (51). Shh expression in the ventral
endoderm induces the WNT2-mediated expression of Nkx2.1, which is critical for lung
bud development and branching morphogenesis as previously discussed (85). In IPF,
activated AT2 cells produce Shh ligand, which then acts as a secreted paracrinesignaling molecule to resident lung fibroblasts (86). The AT2-secrected Shh binds to
fibroblast Ptch1 and activates Gli1/2 to express target genes that increase the
proliferation and migration of fibroblasts and make them resistant to apoptosis while
increasing ECM synthesis (86).
The misexpression of developmental pathways in AT2 cells has more recently
been shown to be a driver of inappropriate repair processes, overactive wound repair
response, and a major contributor to the activation of fibroblasts that perpetuate the
fibrotic phenotype. Other more recent developmental pathways have been identified
including the fibroblast growth factor (FGF), Notch, and the Hippo YAP/TAZ
pathways. Interestingly, the Hippo YAP/TAZ pathway can act through the
amplification of the TGF-β and Shh pathways, which introduces a potential new route
of anti-TGF-β therapy (87). Despite this increased interest in developmental pathway
activation in the alveolar epithelium, there are still many unanswered questions about
how these pathways exert their effect on the AT2 cells, what role they play in the
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epithelial-fibroblast signaling niche, and the AT2 cell injury response. Increased
research into these altered developmental pathways could provide deeper
understanding and insight to the detailed mechanisms underlying IPF and could
provide novel therapeutic targets for this poorly treatable disease. Interestingly,
increased signals for the developmental gene Sine Oculis Homeobox Homolog 1 (Six1)
was identified in RNA-seq data from 3 independent studies (70, 88, 89). Preliminary
results from our lab also demonstrated elevated Six1 levels in IPF and in experimental
models of lung fibrosis. These novel findings showing increased Six1, and the fact that
Six1 is essential for lung development (90, 91) allowed for the formation of the
following overall hypothesis of my thesis. Hypothesis: Six1 expression in the AT2 cells
drives the progression of lung fibrosis.
This thesis proposes the identification of the Six1 developmental pathway in
lung fibrosis. The involvement of Six1 could provide an additional developmental
pathway to study in IPF and could add to our current understanding of the disease
mechanisms of IPF. In the following chapter I will provide more detailed background
on Six1 and the Sine Oculis family of transcription factors and what is known about
their role in development and disease.
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Chapter 2: History of Sine Oculis Family

History of the Sine Oculis (SIX) family
The sine oculis homeobox (SIX) family of conserved transcription factors were
first discovered as critical regulators of the fruit fly (Drosophila melanogaster) visual
system development and as thus the original member of the SIX family was founded as
sine oculis (so) (92). Using the fruit fly as a model, further investigation into the
different SIX family members yielded two additional members: optix and DSix4 (93).
These three distinct subgroups of the SIX family were subdivided based on the highly
conserved structure of the coded proteins, but which showed independent functions
relative to the sine oculis protein(94). The presence of conserved orthologs in the
mouse and how they were regulated in eye development in the fly were used to
decipher these three functional groups. The first study that looked at the differences
between optix and sine oculis showed that ectopic expression of optix, but not sine
oculis, led to ectopic eye expression in the fly (94). This unique role of optix was
further elucidated by showing that it functions independently of the PAX6 fly ortholog
eyeless (ey), whereas sine oculis is downstream of eyeless in the developing eye (94). It
was shown that optix was homologous to the mouse Six3 gene and was important in
the developing visual system with unique expression patterns that are independent of
sine oculis (93). Interestingly, DSix4 mapped to the mouse Six5 gene with high
homology and was found to have similar function (95). An important feature of DSix4
is that although it is highly homologous to sine oculis, it does not play a role in eye
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development but instead is essential to the developing mesoderm structures including
muscle and gonads (96).
In the early 2000’s, large scale sequencing efforts led to many new insights into
developmental biology and allowed for the accurate mapping on ancestral genes and
their associated orthologs that gave scientists insight into potential disease
implications. Such efforts allowed for the discovery of three SIX family orthologs in
several higher order vertebrates, including mice and humans. In each subgroup of the
SIX family in mammals there is a complimentary paralog that is thought to be derived
from an evolutionary duplication event to give rise to two members of each subgroup
in the mammalian SIX family: Six1/2 (sine oculis), Six5/4 (DSix4), and Six3/6 (optix)
(92, 94, 95).

Anatomy of Six1
The SIX family is an evolutionarily conserved family of transcription factors
that are critical in development. All members (Six1-6) of the mammalian SIX family
are expressed in both mice and humans and are characterized by two conserved
domains: the homeobox domain (HD) and the Six domain (SD) (92). The homeobox
domain is responsible for the recognition of a consensus DNA binding motif and is
required for transcription factor binding to the promoters of target genes. Homeobox
domains are generally conserved between other families of transcription factors and
have common features, like the ability to bind a common consensus sequence TAAT
and are 60 amino acids in length (97). Six1 is a 284 amino acid protein with the
homeobox domain representing amino acids 124-184 (98). The general structure of
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HD’s are a triple helix structure with a helix-turn-helix motif with several residues in
the third ‘recognition’ helix giving the DNA binding specificity including residues at
position 47, 50, 51, 54 (92, 97).
The homeobox domain of the SIX family are unique and belong to a subgroup
of HD named K50 HD since they contain a lysine at position 50 of the recognition
helix that gives them wider range of specificity beyond the TAAT motif and
specifically allows for more binding to 5-8 base pair motifs with a cytosine suffix (97).
Six1 has been shown to bind to the myocyte enhancer factor 3 (MEF3) consensus motif
–TCAGGTTTC- with strong affinity and is considered its canonical and most widely
accepted binding motif (99). Recently, it has been shown that Six1 has a much more
diverse ability to bind to several iterations of this MEF3 motif with similar kinetics.
Interestingly, this study provided evidence that specific nucleotide positions were
critical for Six1 binding, including: the prefix T (position 1), although not absolutely
necessary for binding, is shown to add very high binding preference for the core
consensus motif and the suffix C (position 9) is critical for binding (100).
The other conserved domain that is shared by all members of the SIX family is
the 113-150 amino acid SIX domain, and on Six1 is located immediately after the Nterminus and proximal to the HD and spans from residues 11- 124 (98). The Six domain
confers the ability for Six1 to mediate various protein-protein interactions. It is
important to note that although all members of the SIX family contain a proteinbinding SIX domain, they mediate different interactions depending to which subgroup
they belong. The sine oculis derived (Six1/2) and DSix4 (Six4/5) depend on the
interactions between either transcriptional co-activators or co-repressors most notably
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the Eyes absent and Dachshund families (Eya/Dach), respectively. This ability to
complex with both co-activators and co-repressors allows Six1 to act as both a
transcription factor that activates transcription, but also as a transcriptional repressor.
This ability is most likely dictated by cofactor availability and the epigenetics of the
downstream target genes of Six1 in a cell-specific context. Additionally, members of
the SIX family do not all have conserved C-terminal regions. This region has been
shown to contain a sequence that acts as an activation domain in both Six2 and Six4
that allows these proteins to modulate transcriptional activity independent of cofactor binding to the SD, and importantly Six1 does not contain this C-terminal region
(101, 102).

Six1 in Development & Disease
Six1 is an evolutionarily conserved transcription factor that is expressed across
several orders of animals from invertebrates to higher order vertebrates, including
humans. This level of conservation suggests an increasingly critical role in
development of an organism. The importance of Six1 during development has been
shown across several organs the last two decades, with muscle, kidney, and sensory
epithelium being the most widely studied (103-105). In 2004, the link between Six1 and
development of these specific organs was reported to cause the developmental disease
Branchio-Oto-Renal (BOR) syndrome (OMIM 608389, (106)). BOR syndrome is an
autosomal dominant developmental disorder with variable penetrance within families
that consists of branchial fistulae, renal disorders including agenesis and sensineural
hearing loss (107). Six1 involvement in BOR syndrome is an interesting example since
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it correlates very well with the reported mechanisms of Six1 in organogenesis. The
sensineural hearing loss is postulated to be due to the effect of Six1 loss on the
mechanosensitive sensory epithelium in the inner ear and their failure to properly
develop through lack of Six1-Eya1 induced Sox2 activation in these cells during
development (105). Six2 is the critical transcription factor responsible for the
development of the kidney. Interestingly, Six1 was shown to control the transcription
of Six2 in renal epithelial cells and that lack of Six1 signal causes improper epithelial
development analogous to the renal anomalies seen in patients with BOR syndrome
(103).
In addition to developmental disorders, Six1 re-expression has been implicated
in various cancers including esophageal, ovarian, lung and the most studied, breast
cancer (108-111). Transcription factors are critical regulators of developmental
properties and their aberrant re-expression or inappropriate expression in a nondevelopmental, lineage-specific context can lead to cells that display cancer cell
phenotypes with dysregulation of proliferation, apoptosis, repair mechanism and
differentiation (112). Similar to BOR syndrome, the coincidence of Six1 in human
cancer illustrates how the normal developmental role of Six1 is well suited for a cancer
phenotype. In breast cancer, Six1 drives the epithelial-to-mesenchymal (EMT)
phenotype and the increase in cancer stem cells both in vitro and in vivo in animal
models of disease (110). Experimental overexpression of Six1 in the MCF12A nonmalignant breast cancer cell line was sufficient to induce malignant transformation,
and Six1 expression in immortalized human keratinocytes blocked differentiation (113,
114). Malignant transformation in breast cancer by Six1 was shown to increase EMT
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transition through TGF-β and ERK signaling and Six1 expression in human breast
cancer was positively correlated with an increase in functional ERK signaling as shown
by increased phospho-ERK (114). Six1 and TGF-β signaling has been well studied in the
context of breast cancer as one of the main signaling pathways that Six1 can modulate
in multiple ways. Depending on the expression levels of TGF-β, the corresponding
receptors, and the cell context during cancer development, TGF-β signaling can either
play a cancer repressive role or a cancer promoting role (115). Six1 was shown to
increase the transcription of TGF-βR1, which induces a cancer promoting EMT
phenotype in breast cancer (116). Additionally, Six1 increases the transcription of the
mircoRNA (miR) 106b-25 cluster that activates downstream TGF-β signaling through
the targeting of the inhibitory SMAD7 (117). This Six1-TGF-β signaling axis was
subsequently shown to be required for Six1 to mediate an EMT phenotype in cervical
cancer.
The role of Six1 in development is to promote cell survival and proliferation in
order to increase the pool of progenitor cells and inhibit differentiation(118). These
specific functions of Six1 were shown to be adapted to drive the development of
cancer. Six1-induced cell proliferation has been studied in various cancers and it has
been shown to change in a cell dependent context through multiple mechanisms and I
will further discuss a few examples that are within the scope of this project(119). Using
the MCF12A breast cancer cell line it was first shown that forced overexpression of Six1
increased the proliferation of these cells through the direct binding and transcription
of cyclin A1 (120). These observations were repeated using MCF7 and 21PT cancer cell
lines where Six1 was overexpressed with concomitant increase in cyclin A1 as well as
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Six1 knockdown showing reduced cyclin A1 levels, decreased proliferation and smaller
tumor size in vitro and in vivo (120). A similar mechanism was reported in pancreatic
cancer models using the PANC-1 cell line that showed similar increase in proliferation
of Six1 overexpressing cells with subsequent decrease with Six1 knockdown, as well as
mouse xenograft models showing increased tumor size (~6-fold) compared to
controls, except this was through direct activation of cyclin D1 in this cell context (121).
In addition, Six1 is also expressed in neurological cancers including glioblastoma
multiforme (GBM) and medulloblastoma (122, 123). In medulloblastoma, Six1 was
shown to increase the transcription of glioma-associated oncogene family zinc finger-2
(GLI2), which is a downstream mediator of Shh signaling which increases proliferation
(123). This is in contrast to GBM were Six1 was not shown to directly increase a cellcycle mediator or canonical proliferative signaling pathway, but instead increased the
production of connective tissue growth factor (CTGF) which changed the tumor
microenvironment to a pro-proliferative environment which then allowed for more
proliferation of the cancer cells (122). In contrast, Six1 was also shown not to increase
the proliferation of human or mouse colorectal cancer (CRC) cell lines in vitro,
however in vivo recruited tumor associated macrophages that stimulated an increase
in proliferation and increase in size using mouse xenograft models (124). This data
adds to the rationale that Six1 is extremely context dependent and cell-specific in how
it functions in vivo in different disease states with unique mechanisms in different
tissues.
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Most relevant to my project, Six1 is an essential transcription factor for normal
lung morphogenesis in utero (90). It has been shown that Six1 is increased in the distal
lung epithelial and mesenchymal cells, just before declining in the saccular stage when
epithelial differentiation is occurring (91). In Six1-/- mice, the lungs are disrupted
leading to subsequent pulmonary hypoplasia that is characterized by the reduction in
epithelial branching and increased mesenchymal proliferation (90). It was also shown
that Six1-/- mice displayed weakened pulmonary vasculature and subsequent
pulmonary hemorrhage with no defects in the endothelium or capillary network. This
suggests that Six1 is responsible for the differentiation of the vascular smooth muscle
and is hypothesized to be due to the downregulation of FGF-10 signaling (90). In the
distal epithelial compartment of Six1-/- mice, the alveolar epithelial differentiation
markers SPC, SPB, and CC10 were increased between 1.7-2.2 fold compared to Six1expressing lungs (90). In total, this shows that the depletion of Six1 later in lung
development is necessary for epithelial differentiation of progenitor cells into AT1 and
AT2 cells in the alveoli and subsequent premature deletion of Six1 leads to epithelial,
vascular, and mesenchymal abnormalities.
In contrast, in adult lung pathology the increased expression of Six1 in patients
with non-small cell lung cancer (NSCLC) results in a poor prognosis and higher
mortality. Six1 was also shown to increase the invasion of NSCLC through the
induction of an EMT phenotype by which the defining characteristics of the epithelial
cell such as cell polarity and cell adhesion are replaced by more mesenchymal-like
migratory properties capable of transitioning into multiple cell types (125, 126).
Although Six1 has not been previously studied in non-cancer lung disease, recently it
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was proposed to be involved in asthma (127, 128). These papers explored the role of
Six1 in a mouse model of asthma and looked at in vitro experiments to show how Six1
increased an EMT phenotype through a TGF-β1-mediated pathway. Although this was
not in IPF or any model of lung fibrosis these studies add to the rationale of my
project to study Six1 in lung fibrosis. This thesis explores the current deficit of
knowledge with regard to Six1 in lung fibrosis and will expand on this idea in the next
chapter.
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Chapter 3: Determining the role of Six1 expression in the development of
pulmonary fibrosis.
A portion of this chapter is based on data and figures that are currently under review.

Wilson, C, Mertens TCJ, Bi W, Collum SD, Wareing N, Ko J, Weng T, Naikawadi RP,
Wolters PJ, Maire P, Jyothula SK, Rajagopal K, Thandavarayan RA, Bruckner BA, Ren
D, Huang HJ, Dickey BF, Ford HL and Karmouty-Quintana H (2019). Sine Oculis
Homeobox Homolog 1 (Six1) Plays a Critical Role in the Progression of Pulmonary
Fibrosis. JCI Insight. (In review)

Rationale
Six1 is critical for the proper development of the alveolar epithelium and is
present through the saccular stage of lung development in mice (90). The pathogenic
expression of Six1 has been shown to promote the invasion of non-small cell lung
cancer (NSCLC) (125, 126). Although Six1 has not been previously studied in noncancer lung disease, recently it was proposed to be involved in asthma (127, 128).
Importantly, these two studies looked at Six1 in an ovalbumin mouse model of asthma
and in a bronchial epithelial cell line (16HBE) to show that RNAi knockdown of Six1
decreased OVA-challenged inflammation, infiltration and mucus production, and Six1
siRNA-treated-16HBE cells suppressed TGF-β1-mediated EMT with a decrease in
fibronectin and collagen IV expression. While these studies are important and add to
the rationale to study Six1 in lung disease, they do not address Six1 in human IPF or in
mouse models of fibrosis as I present in this current study.
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Importantly in the context of IPF, we found increased Six1 levels in the data
from a study using microarray to look at the differential gene expression of whole lung
tissue of IPF patients (129), as well as in an AT2-specific single cell RNA-sequencing
(scRNA-Seq) data set that showed increased AT2 (CD326+, HTII-280+) cell-specific
expression of Six1 in IPF patients (130). However, these studies did not demonstrate if
Six1 is expressed at the protein level or if it contributes to lung fibrosis and to our
knowledge there are no current studies that investigate the role of Six1 in IPF. Thus, I
hypothesized that Six1 expression is elevated in IPF and that it is a causative agent in
lung fibrosis that can be targeted therapeutically. In this study, I built upon this
hypothesis and in this chapter demonstrate that there is increased Six1 transcript and
protein expression in IPF compared to healthy controls. I also demonstrate that
conditional deletion of Six1 in AT2 cells in mice can significantly halt development of
lung fibrosis.

Results
Sine Oculis Homeobox Homolog 1 (Six1) and its transcriptional co-activators Eya1 and
Eya2 are elevated in IPF.
Since previous studies had shown the recapitulation of developmental genes in
IPF, I first analyzed results from a DNA microarray that was performed using lung
tissue samples from patients with a diagnosis of IPF (n=6) compared to healthy
controls (n=2) to compare the upregulated differentially expressed genes (DEG)
focusing on developmental pathways. This revealed an approximate 8-fold increase in
Six1 expression in IPF samples concomitant with a 4 and 3-fold upregulation of Eya1
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and Eya2, respectively (Fig. 1 A). Six1, Eya1, and Eya2 levels were increased to the same
or greater degree as COL1A1, COL1A2 or genes associated with a previously published
IPF transcriptomic signature (129) (Fig. 1 A). Next, to confirm the microarray data, I
quantified the expression of Six1, Eya1, and Eya2 mRNA by RT-qPCR in IPF (n=24),
COPD (n=18) and healthy controls (n=12) and protein by immunoblot in IPF (n=7) and
healthy controls (n=7). It is important to note that COPD was chosen to use as an
additional chronic lung injury state that also affects the alveoli region of the lungs, but
through the destruction of elastin, increase in compliance, and loss of tissue as
opposed to the excess of ECM, decrease in compliance and destruction of the alveoli
in IPF. It was used as a more appropriate age-matched tissue to determine whether
Six1 expression is age or pan chronic lung injury dependent. We found significant
increases in both mRNA and protein expression of Six1, as well as both Eya1 and Eya2
(Fig. 1 B-E).
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Figure 1. Six1 and co-activators Eya1 and Eya2 are elevated in IPF. (A) Microarray
showing Six1 (arrow), Eya1, and Eya2 (all 3 highlighted in red) expression fold change
in IPF lungs relative to healthy controls. (B)-(D) Six1, Eya2, and Eya1 mRNA expression
in IPF (n=21) compared to COPD (n=18) and control lungs (n=12). (E) Western blot
showing protein expression of Six1, Eya1, and Eya2 in IPF (n=7) versus control lungs
(n=7) Data shown + SEM *p < 0.05 (comparing control to IPF), # p < 0.05 (comparing
COPD to IPF) using one-way ANOVA with Holm-Sidak post hoc test.
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Increased Six1 levels are localized to alveolar epithelial type 2 (AT2) cells
In order to determine the localization of increased Six1 signals in IPF, I
performed immunohistochemical (IHC) staining for Six1. Dual staining for Six1 and
surfactant protein C (SPC) showed AT2-specific localization (Fig. 2 A, red arrows) of
Six1 (red/brown signal) in surfactant protein C (SPC, blue signal) positive cells. We
confirmed AT2 localization by isolating AT2 (SPC+) cells from IPF and control lungs
to compare Six1 and Eya1/Eya2 gene expression. AT2 cells were identified by the
presence of SPC by immunofluorescence imaging (Fig. 2 B, C). We demonstrated that
Six1 and both Eya1 and Eya2 mRNA expression was increased in AT2 cells isolated from
IPF patients compared to controls (Fig. 2 D-F). I then subsequently demonstrated Six1
and SPC RNA co-localization using RNA in situ hybridization that identifies an
increased positive Six1 signal (cyan) with SPC (red) in IPF lungs (Fig 3 B) compared to
controls (Fig 3 A). These results demonstrate that in IPF, Six1, Eya1, and Eya2
expression levels are upregulated in AT2 cells.
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Figure 2. Six1 and co-activators Eya1 and Eya2 are localized to the AT2 cells in IPF
(A) IHC staining of IPF lung (40X) with expanded area showing type II alveolar epithelial
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cells (denoted with red arrows) with co-localization of surfactant protein-C (blue) and
Six1(red/brown) (B) 10X image showing surfactant protein-C (SPC, green) and DAPI
staining of AT2 cells isolated from IPF lungs with 20X (C) image. (D)-(F) Transcript levels
of Six1, Eya1 and Eya2 in isolated AT2 cells from IPF (n=5) compared to control lungs (n=5).
Data shown + s.d. *p < 0.05 using two-tailed, unpaired Student’s t test with Welch’s
correction.

Figure 3. Six1 and Surfactant protein C (SPC) co-localization in AT2 in IPF by RNA in
situ hybridization. (A) Control lung samples (n=5) labeled by RNA in situ hybridization
with SPC (red) and Six1 (cyan) probes at low-power field (LPF, 20X) and high-power field
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(HPF, 40X). (B) IPF lung samples (n=5) labeled by RNA in situ hybridization with SPC
(red) and Six1 (cyan) probes at low-power field (LPF, 20X) and high-power field (HPF, 40X)
showing SPC and Six1 co-localization (arrows). All samples are counterstained with
hematoxylin.

Six1 is upregulated in two distinct mouse models of pulmonary fibrosis.
The bleomycin (BLM) mouse model is a widely utilized model system for the
study of fibrotic lung disease (131). We used a chronic, low-dose intraperitoneal (IP)
model of BLM injury (Fig. 4 A) (132, 133), which has the advantages that fibrotic
deposition is observed in a sub-pleural distribution, which more closely resembles
human disease with fibrotic scarring that is not typically reversible. BLM models do
not recapitulate all features of human disease (55) and in recent years genetic models
of spontaneous lung fibrosis have been explored (67). Recently, it has been shown that
mice lacking the telomere shelterin protein, telomere repeat binding factor 1 (TRF1)
(67) in their AT2 cells develop spontaneous lung fibrosis after 9 months, thus
providing a model that parallels what is known about telomere maintenance
dysfunction in IPF (Fig. 4 B).
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Figure 4. Schematics of I.P. BLM and TRF1 models of lung fibrosis. (A)
Representative model of the intraperitoneal (I.P.) bleomycin (BLM) of lung fibrosis
giving C57Bl/6 mice 2 injections/week for 4 weeks of BLM (0.035U/g) followed by
physiological readouts, including lung function and tissue collection on day 33. (B)
Representative model of the telomere repeat binding factor 1 (TRF1) mouse model of
lung fibrosis. AT2-specific deletion of TRF1 using the Spc-Cre TRF1fl/fl and the TRF1fl/fl
control mice following weekly injection of Tamoxifen (250mg/kg) for 9 months that is
accompanied by spontaneous development of lung fibrosis in the Spc-Cre TRF1fl/fl
mice.
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Using the BLM model, we observed an increase in Six1, Eya1 and Eya2 transcript
and protein expression levels (Fig. 5 A, B). In collaboration with Dr. Paul Wolters and
Dr. Ram Naikawadi at the University of California San Francisco, we determined levels
of Six1 in isolated AT2 cells from the conditional AT2-specific TRF1 (Spc-Cre TRF1fl/fl)
mouse model. These studies revealed increased Six1, Eya1, and Eya2 levels in the AT2
cells of these mice at 9 months post tamoxifen treatment (Fig. 5 C).
Immunofluorescence imaging of Spc-Cre TRF1fl/fl lung sections demonstrated
increased Six1 and co-localization with AT2 (Spc+) cells compared to TRF1fl/fl control
mice (Fig. 5 D). Taken together, our results demonstrate that Six1, Eya1 and Eya2 are
increased in two distinct experimental models of fibrotic lung disease.
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Figure 5. Six1 is upregulated in two distinct mouse models of pulmonary
fibrosis. (A) Six1 mRNA levels and (B) Six1, Eya1, and Eya2 protein expression in C57Bl/6
mice treated with 8 injections of bleomycin (BLM, 0.035 U/g). (C) Six1, Eya1, and Eya2
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mRNA expression in AT2 cells isolated from Spc-Cre TRF1fl/fl and TRF1fl/fl control mice. (D)
Immunofluorescence image (40X magnification) of Six1 (green signal) expression and the
co-localization with Spc+ (red signal/merged) cells in lung tissue from SPC-Cre TRF1fl/fl
and TRF1fl/fl control mice. Data shown + s.d. *p < 0.05 using two-tailed, unpaired Student’s
t test.

Deletion of Six1 from AT2 cells protects mice from BLM-induced lung fibrosis
Embryonic deletion of Six1 was shown to be lethal due to impaired epithelial
branching with mesenchymal hyperplasia leading to severe lung hypoplasia and
respiratory failure (91). Thus, in order to evaluate whether Six1 plays a
pathophysiological role in lung fibrosis, we had to generate a tamoxifen-inducible
conditional AT2-specific Six1 knockout mouse (iAT2Six-/-) using previously described
surfactant protein-C (SPC) CreERT2 (134) and Six1 loxP/loxP mice (135). Using the IP
BLM model, Six1 was deleted 14 days prior to BLM exposure (Fig. 6 A). To confirm the
deletion of Six1 from AT2 cells following BLM treatment we performed Six1 RNA in
situ hybridization with co-IHC with SPC (Fig. 6 B). These experiments demonstrated
that mice lacking Six1 in AT2 cells (iAT2Six-/-,Fig 6 D) did not develop significant
fibrosis observed histologically compared to BLM-treated Six1 competent Creexpressing control mice (iAT2Cre, Fig 6 C) as assessed by Masson’s Trichrome showing
significantly reduced Ashcroft scores (Fig. 6 E). These changes were also consistent
with reduced soluble collagen concentration in bronchoalveolar lavage fluid (BALF) of
iAT2Six-/- mice compared to control iAT2Cre mice (Fig. 6 F).
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Figure 6. Deletion of Six1 from AT2 cells protects mice from BLM-induced lung
fibrosis. (A) Experimental BLM model with pretreatment of tamoxifen. (B)
Representative RNA in situ hybridization images showing the absence of Six1 (136) signal in
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tamoxifen-treated, BLM-exposed iAT2Six1-/- (scale bar, 50um) and the presence of Six1
colocalized with SPC (blue) in tamoxifen-treated, BLM-exposed iAT2Cre mice (scale
bar,100um). (C) Representative Masson's trichrome staining in low power field (scale bar,
200um) and (D) higher power field (scale bar, 100um). (E) Ashcroft scores. (F) Soluble
collagen concentration (mg/ml) in bronchoalveolar lavage fluid (BALF).

Consistent with histological analyses, transcript expression levels of Col1a1,
Col1a2, Col2a1, and Fn from isolated whole lung tissue were increased in BLM-exposed
iAT2Cre mice compared to PBS-exposed iAT2Cre and BLM-exposed iAT2Six-/- mice (Fig 7
A-D). Since a hallmark of fibrosis development is the differentiation of fibroblasts to a
myofibroblast phenotype (1, 14) we looked at the myofibroblast marker aSMA. We
observed a significant reduction in myofibroblast development in BLM-exposed
iAT2Six-/- compared to BLM-treated iAT2Cre mice, along with an improvement in
alveolar architecture with reduced septal thickness (Fig. 7 E). Together, these
experiments demonstrate the anti-fibrotic capacity of Six1 deletion in AT2 cells.
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Figure 7. Six1 deletion from AT2 reduces expression of pro-fibrotic transcripts
and alpha smooth muscle actin (aSMA). (A)-(D) RT-qPCR of Col1a1, Col1a2, Fn, and
Col2a1. Data shown + SEM. * p < 0.01 (comparing iAT2Cre PBS vs BLM), # p < 0.01
(comparing iAT2Cre BLM vs iAT2Six-/- BLM), using one-way ANOVA with Holm-Sidak post
hoc test. (E) Alpha-smooth muscle actin (a-SMA) IHC (red signal) with DAPI counterstain.
Deletion of Six1 from AT2 cells improves lung function in BLM-exposed mice
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The successes of experimental therapeutics in animal models of lung fibrosis
often rely on the attenuation of histologic and molecular indices of lung fibrosis (e.g.,
collagen content assays, histological scoring and fibrotic gene expression). However in
humans, disease progression in IPF patients is often determined using CT imaging and
lung function analyses (137), as such we performed lung function analyses in BLMexposed mice. I used the well described forced oscillation technique (138) to assess
lung mechanics in mice. The use of complex oscillatory air waveforms at different
frequencies at the airway opening of the animal allows for the decomposition of the
separate frequencies using a Fourier transform and fitting the output signals using
mathematical modeling in order to differentiate between the airways (central and
peripheral), alveolar and parenchyma (139-141). This becomes very useful as a
quantifiable and physiologically relevant endpoint in the assessment of lung fibrosis.
The parameters assessed were the whole respiratory system parameters, including
whole-respiratory elastance (Ers) and whole-respiratory resistance (Rrs) as well as the
alveolar-specific parametes tissue damping (G) and tissue elastance (H). The elastance
is the measure of the elastic recoil forces that opposes the expansion of the lungs. Rrs
is the sum of the resistance of the airways (Rn) and the lung tissue resistance. In lung
fibrosis the distal lung becomes thick and non-compliant which subsequently
increases the lung tissue resistance while the Rn is unaffected (142, 143). For this
reason, Rn was used as an internal control for all subsequent experiments. This causes
an increase in Rrs due to the fibrotic damage in the distal lung. G and H are measures
of tissue resistance and elastance, respectively which are analogous to the wholerespiratory parameters but are restricted to the distal lung to provide compartment51

specific information. In lung fibrosis the decrease in lung compliance (Cst) can be
measured through the use of pressure-volume loops (PV loops) that can be used to
assess the overall lung distensibility for a given pressure(142). Since the fibrotic lung is
stiff and non-distensible, the compliance is lowered compared to healthy controls.
Reference values and descriptions of all measured parameters used in this study for
both healthy and fibrotic mice are included in table 1 and are derived from the
following studies (139-143).

Reference Values
Parameter

Units

Inspiratory Capacity
(IC)

mL

Whole Respiratory
Resistance (Rrs)
Whole Respiratory
Elastance (Ers)

cmH2O.s/mL
cmH2O/mL

Newtonian
Resistance (Rn)

cmH2O.s/mL

Tissue Damping (G)

cmH2O/mL

Tissue Elastance (H)

cmH2O/mL

Static Compliance
(Cst)

mL/cmH2O

Description
Healthy
Volume of air that can be
inhaled after the end of a
0.8
normal expiration
Quantitatively assesses
the level of constriction
0.5
in the lungs
Measure of the elastic
stiffness of the
17
respiratory system
Resistance of the large
0.25
conducting airways
Amount of energy that is
lost to heat within the
tissues as a result of
3
friction. Measure of the
tissue resistance
Ability of the tissue to
retract and revert to its
original shape. Used as
22
an index of tissue
stiffness
Measurement of the
intrinsic elastic
properties of the
respiratory system at
0.08
rest. Describes the
volume of respiratory
system expansion per
unit pressure
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Fibrosis
0.35
0.85
60

0.25
8
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0.035

Forced Vital
Capacity (FVC)

Forced Expiratory
Capcity in 0.1sec
(FEV0.1)

mL
mL

Total volume expired
during a forced
expiration
Volume expired during
the first 0.1 seconds of a
forced expiration

1.0

0.6

0.8

0.6

Table 1. Description of in vivo lung function parameters measured using the
forced oscillation technique with expected outcomes for healthy and fibrotic
mice.

These experiments revealed that BLM-exposed iAT2Six-/- mice showed
significant improvement in all measured parameters compared to BLM-treated iAT2Cre
mice, including decreased whole respiratory elastance (Ers) and resistance (Rrs) (Fig. 8
A, B), improved parenchymal tissue damping (G) and tissue elastance (H) (Fig. 8 C,
D), and increased inspiratory capacity (IC) and static compliance (Cst) (Fig. 8 E, F).
The pressure-volume curve for iAT2Six-/- mice still demonstrated a slightly more
restrictive pattern compared to PBS controls (Fig. 8 G), but revealed significant overall
improved lung mechanics compared to BLM-treated iAT2Cre control mice. Upper
airway Newtonian resistance (Rn) showed no significant difference amongst all
treatment groups (Fig. 8 H) and served as our internal control since we did not
anticipate any increase in the central/conducting airway resistance following IP BLMinduced fibrosis (132). Taken together, these results demonstrate that prophylactic
deletion of Six1 prior to BLM-exposure protects mice from the development of lung
fibrosis observed both histologically and physiologically.
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Figure 8. Deletion of Six1 from AT2 cells improves lung function in BLMexposed mice. (A) Whole respiratory elastance (Ers) and (B) resistance (Rrs) measure
using the single frequency flexiVent forced oscillation (138) perturbation under closed
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chest conditions. (C-D) Partitioned, broadband FOT showing tissue damping (G) and
tissue elastance (H). (E-G) Inspiratory capacity (IC) with static compliance (Cst) and
pressure-volume (PV) curve (G) using a ramp-style pressure-driven (PVr-P) maneuver,
iAT2Six-/- PBS excluded from graph (G) for clarity. (H) Newtonian resistance (Rn) of central
airways. Data shown + s.d. * p < 0.05 (comparing iAT2Cre PBS vs BLM), # p < 0.05
(comparing iAT2Cre BLM vs iAT2Six-/- BLM), using One-way ANOVA with Holm-Sidak post
hoc test.

Discussion
Six1 is an essential transcription factor for normal lung morphogenesis in utero
(90) and is normally not expressed in most adult tissues. Absence of Six1 in mice leads
to severe epithelial branching abnormalities and pulmonary hypoplasia, underscoring
the vital role Six1 plays in normal lung development (90, 91). In contrast, the increased
expression of SIX1 in patients with non-small cell lung cancer (NSCLC) results in a
poor prognosis and higher mortality. Six1 was shown to increase the invasion of
NSCLC through the induction of an EMT (125, 126). Although Six1 has not been
previously studied in lung fibrosis, recently it was proposed to be involved in asthma
(127, 128). However, with that being noted, one limitation of this current study is that
while these data show that Six1 expression is increased in IPF and is significantly lower
in COPD, it does not fully explain whether this is a fibrotic specific process or chronic
lung injury mediated, and therefore further investigation into other chronic fibrosisassociated lung

diseases

like

Systemic Sclerosis-ILD (SSc-ILD) or

Hypersensitivity Pneumonitis (HP) is needed.
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chronic

Importantly, in this study we present novel findings that the developmental
transcription factor, Six1, plays a role in the development of fibrosis. I demonstrate
that both mRNA and protein expression of Six1 and the transcriptional co-activators
Eya1 and Eya2 are increased in IPF and two mouse models of lung fibrosis. This signal
was then localized to the alveolar epithelium, specifically the AT2 cells, which are
critical players in the pathogenesis of fibrosis by showing both RNA and protein based
staining in IPF lungs with the increased gene expression of Six1, Eya1 and Eya2 in
isolated human AT2 cells from IPF patients. I also demonstrate that AT2-specific
deletion of Six1 can improve the histological architecture, fibrotic deposition, fibrotic
mediator expression and lung mechanics prophylactically. These data demonstrate
that Six1 is elevated in IPF and mouse models of lung fibrosis but does not answer if it
is causative of lung fibrosis or how it functions in the AT2 cells. These questions will
be explored in the next chapter.
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Chapter 4: Evaluating the role of Six1 in the lung alveolar epithelial type II cells.
A portion of this chapter is based on data and figures that are currently under review.

Wilson, C, Mertens TCJ, Bi W, Collum SD, Wareing N, Ko J, Weng T, Naikawadi RP,
Wolters PJ, Maire P, Jyothula SK, Rajagopal K, Thandavarayan RA, Bruckner BA, Ren
D, Huang HJ, Dickey BF, Ford HL and Karmouty-Quintana H (2019). Sine Oculis
Homeobox Homolog 1 (Six1) Plays a Critical Role in the Progression of Pulmonary
Fibrosis. JCI Insight. (In review)

Rationale
Importantly, in this thesis I have presented novel findings that the
developmental transcription factor, Six1, is elevated in fibrotic lung disease. I highlight
the concept and provide evidence that the alveolar epithelium, specifically AT2 cells,
are critical players in the pathogenesis of fibrosis by showing that AT2-specific
deletion of Six1 can improve the histological architecture, fibrotic deposition, fibrotic
mediator expression and lung mechanics prophylactically. AT2 cells have been shown
to be a central component in the pathogenesis of IPF (14). AT2 cells are shown to have
significant epithelial plasticity to allow for repair of the injured alveolar space, and in
IPF they have been shown to inappropriately express developmental gene pathways
(51, 70, 86). The role of Six1 in development is to promote cell survival and
proliferation in order to increase the pool of progenitor cells and inhibit
differentiation(118). These specific functions of Six1 are shown to be adapted to drive
the development of cancer. Six1-induced proliferation of cancer cells has been studied
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in various cancers and it has been shown to change in a cell dependent context
through multiple mechanisms (119). However, the function of Six1 in AT2 cells has not
been explored and is not known.
In this chapter, I propose a novel mechanism whereby Six1 modulates
macrophage migration inhibitory factor (MIF) expression in AT2 cells that is
important for the progression of lung fibrosis. MIF is a proinflammatory and
profibrotic cytokine that has been shown to be increased in several chronic lung
diseases including IPF, pulmonary arterial hypertension (PAH), asthma, and in fibrotic
disorders including skin fibrosis of patients with both limited (lSSc) and diffuse (dSSc)
systemic sclerosis, renal, and cardiac fibrosis (144-151), however how MIF is regulated
and it’s role in IPF is not fully understood. Importantly, using a bleomycin (BLM)
model of lung fibrosis, we demonstrate an increase in MIF expression in BLM-treated
mice with significant reduction of both MIF transcript levels and secreted MIF protein
in bronchoalveolar lavage fluid (BALF) in BLM-treated mice following conditional
deletion of Six1 from the AT2 cells.

Results
AT2 Six1 overexpression in vivo does not lead to impaired lung function in 3 months, but
shows increase in DNA damage.
The previous data demonstrates that deletion of Six1 from AT2 cells improves
markers of fibrosis in BLM-treated mice. However, while this suggests that Six1 is
important for fibrosis development it does not answer whether it is causative. In order
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to study this question, I generated an AT2 specific Six1 overexpression (SixTET) mouse
using mice consisting of a human Six1 construct downstream of tet operator sequences
(as described,(152)) with the surfactant protein C (SFTPC) reverse tetracycline
transcriptional activator (rtTA) driver (Fig. 9 A). I isolated AT2 cells from the four
possible genotypes with the AT2 specific Six1 overexpression SixTet;Spc-rtTA (SixTET)
and the SixTet only, Spc-rtTA only and C57Bl6 control mice at day 14 of doxycycline
exposure and showed increased Six1 protein expression by immunoblot (Fig 9 B). I
also demonstrate the presence of Six1 mRNA (arrows; pink signal) in SixTET compared
to Spc-rtTA using RNA in situ hybridization (Fig 9 C).
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Figure 9. AT2 specific Six1 expression in SixTET mice following 14 days of
doxycycline treatment. (A) Representative model of the SixTet;Spc-rtTA (SixTET)
genetics using the surfactant protein C (SFTPC) reverse tetracycline transcriptional
activator (rtTA) driver under the control of doxycyline activation. (B) Western blot of
isolated AT2 cells from the 4 possible genotypes used for the generation of the SixTET
mice, in order from (1) C57Bl/6, (153) SixTet only, (3) Spc-rtTA only, and (4)
SixTet;Spc-rtTA (SixTET). (C) RNA in situ hybridization of Spc-rtTA control mice and
SixTET showing expression of Six1 (pink) in SixTET mice following doxycycline
treatment. Scale bar represents 20um.

For all subsequent experiments I used the Spc-rtTA mice as controls given that
they are analogous to Cre-expressing mice where the Spc-rtTA express a foreign
protein that could have the greatest potential for confounding future experimental
results. I then assessed mice at day 14 after induction with doxycycline for any
physiological changes in lung function. I showed no significant difference between
SixTET and Spc-rtTA control mice in all measured parameters, including whole
respiratory elastance (Ers) and resistance (Rrs) (Fig. 10 A, B), parenchymal tissue
damping (G) and tissue elastance (H) (Fig. 10 C, D), or inspiratory capacity (IC) (Fig. 10
E).
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Figure 10. Six1 over expression in AT2 cells for 14 days does not significantly
change lung function. (A) Whole respiratory elastance (Ers) and (B) resistance (Rrs)
measure using the single frequency flexiVent forced oscillation (138) perturbation under
closed chest conditions. (C-D) Partitioned, broadband FOT showing tissue damping (G)
and tissue elastance (H). (E) Inspiratory capacity (IC). Data shown + s.d. with n.s denoting
no significant difference between SixTET and Spc-rtTA control mice using two-tailed,
unpaired Student’s t test.
61

I then assessed whether chronic overexpression of Six1 for 3 months led to
impaired lung function. Following 3 months of doxycycline, we did not observe any
significant change in parameters comparing SixTET to the Spc-rtTA mice, including in
Rrs and Ers (Fig. 11 A, B), IC, Cst (Fig. 11 C, D), and the negative-pressure expiratory
parameters forced vital capacity (FVC) or forced expiratory volume (FEV0.1) (Fig 11
E,F). Interestingly, we did observe the phosphorylation of histone variant H2AX at Ser
139 (γ-H2AX) as a marker of increased DNA damage in SixTET mice compared to SpcrtTA controls as assessed by immunoblot (Fig. 11 G).
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Figure 11. Six1 over expression in AT2 cells for 3 months does not significantly
change lung function, but shows phosphorylation of histone variant H2AX at
Ser 139 (γ-H2AX). (A) Whole respiratory resistance (Rrs) and elastance (Ers)(B) measure
using the single frequency flexiVent forced oscillation (138) perturbation under closed
chest conditions. (C) Inspiratory capacity (IC) and (D) Static compliance (Cst) using a
ramp-style pressure-driven (PVr-P) maneuver. Negative-pressure expiratory parameters
forced vital capacity (FVC; E) or forced expiratory volume (FEV0.1; F). (G) Western
blot showing positive γ-H2AX signal in SixTET mice compared to Spc-rtTA control.
Data shown + s.d. with n.s denoting no significant difference between SixTET and SpcrtTA control mice using two-tailed, unpaired Student’s t test.

Overexpression of Six1 in AT2 cells increases mortality and exacerbates fibrosis
development.
The demonstration that Six1 overexpression between 14 days and 3 months did
not lead to significant physiological alterations in lung function by itself, I then aimed
to investigate whether conditional overexpression of Six1 in AT2 cells in the presence
of a secondary injury would then lead to an exacerbated fibrotic phenotype. Upon
exposure of SixTET mice to a secondary insult like IP BLM treatment, I observed a
significant increase in mortality compared to Spc-rtTA mice (Fig 12 A). We
demonstrate an increase in histological fibrotic burden in BLM-treated SixTET
compared to Spc-rtTA controls as assayed using Ashcroft scoring of Masson’s
trichrome staining (Fig. 12 B, C) and increased Six1, Col1A1, Col2A1, and FN gene
expression in SixTET mice (Fig 12 D-G).
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Figure 12. Overexpression of Six1 in AT2 cells increases mortality and
exacerbates fibrosis development. (A) Kaplan-Meier survival curve of SixTET and
Spc-rtTA treated with IP BLM for 33 days. (B) Ashcroft scores (C) Representative
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Masson's trichrome staining; scale bar, 100um. (D-G) RT-qPCR of Six1, Col1a1, Col1a2, and
Fn. Data shown + SEM. * p < 0.01 using the Mann-Whitney test.

These findings were consistent with in vivo lung function assessment that revealed a
significant decline in lung function including increased whole respiratory elastance
(Ers) and resistance (Rrs) (Fig. 13 A, B) in BLM-SixTET compared to BLM-Spc-rtTA
mice, increased lower airway tissue damping (G) and tissue elastance (H) (Fig. 13 C,
D), and decreased inspiratory capacity (IC) and static compliance (Cst) (Fig. 13 E, F).
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Figure 13. Overexpression of Six1 in AT2 cells in mice treated with BLM worsens
lung function. (A) Whole respiratory elastance (Ers) and (B) resistance (Rrs) measure
using the single frequency flexiVent forced oscillation (138) perturbation under closed
chest conditions. (C-D) Partitioned, broadband FOT showing tissue damping (G) and
tissue elastance (H). (E-F) Inspiratory capacity (IC) with static compliance (Cst) using a
ramp-style pressure-driven (PVr-P) maneuver. Data shown + s.d. * p < 0.05 comparing
SixTET mice to Sp-rtTA controls using Mann-Whitney test.
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AT2 cell overexpression of Six1 does not promote an EMT or senescent phenotype
I demonstrated that conditional Six1 overexpression in AT2 cells worsens the
fibrotic phenotype in mice, however how Six1 affects the AT2 cell during this process
remained unclear. In breast cancer, Six1 drives the EMT phenotype and the increase in
cancer stem cells both in vitro and in vivo in animal models of disease (110).
Experimental overexpression of Six1 in the MCF12A non-malignant breast cancer cell
line was sufficient to induce malignant transformation (113, 114). Malignant
transformation in breast cancer by Six1 was shown to increase EMT transition through
TGF-β signaling (114). Six1 was shown to directly increase the transcription of TGF-βR1,
which induces a cancer promoting EMT phenotype in breast cancer (116). Given that
this was a demonstrated direct target of Six1 in breast cancer and that increased TGF-β
signaling is so well studied in IPF with AT2 cell EMT (154) being reported as a
potential contributor to IPF progression, I used the MLE 12 mouse AT2 cell line and
overexpressed both mouse Six1 (mSix1) and human Six1 (hSix1) for 48 hours (Fig 14, A,
B) similar to the previous cancer studies to assess whether there was an increase in
either the known direct targets of Six1 or EMT markers. Interestingly, there were no
significant changes in gene expression using RT-qPCR of TGF-βR1 or the EMT markers
Zinc Finger E-Box Binding Homeobox 1 (Zeb1), Snail Family Transcriptional Repressor
1 (Snai1), or E-cadherin (CDH1) (Fig14, B-E).
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Figure 14. AT2 cell overexpression of Six1 does not increase EMT markers. (A)
Western blot of MLE12 cells overexpressing either GFP, mouse Six1 (mSix1), or human
Six1 (hSix1) for 48 hours. (B-F) RT-qPCR of Six1, TGF-βR1, and EMT markers Zinc
Finger E-Box Binding Homeobox 1 (Zeb1), Snail Family Transcriptional Repressor 1
(Snai1), or E-cadherin (CDH1). Data shown + s.d. with n.s denoting no significant
difference between using two-tailed, unpaired Student’s t test.
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An additional active area of research in lung fibrosis is AT2 cell senescence.
Given the data that showed increased DNA damage through the phosphorylation of γH2AX in SixTET mice compared to Spc-rtTA controls at 3 months without any
additional chemical or drug-induced lung injury, I looked at whether Six1 induced an
increase in senescence markers in the same population of mice.

Comparing the

expression of p16 and p21 in SixTET mice at 3 months did not demonstrate an increase
in either gene expression or protein accumulation of p21 or p16 compared to Spc-rtTA
controls as measured by RT-qPCR and immunoblot, respectively (Fig 15 A-C). When
the SixTET and Spc-rtTA controls were exposed to BLM injury there was an increase
in both p16 and p21 in both mRNA expression and protein levels (Fig 15 D-F), but the
difference between both groups was not significant.
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Figure 15. AT2 cell overexpression of Six1 does not promote a senescent
phenotype. (155) RT-qPCR and Western blot of p16 (Cdkn2a1) and p21 (Cdkn1a1),
respectively, in SixTET and Spc-rtTA controls exposed to doxycycline for 3 months (DF) Western blot and RT-qPCR and of p16 (Cdkn2a1) and p21 (Cdkn1a1), respectively in
SixTET and Spc-rtTA controls treated with IP BLM. Data shown + s.d. with n.s denoting
no significant difference between using two-tailed, unpaired Student’s t test. Note: the Six1
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and GAPDH control blots in (C) appeared in Figure 11 (G) and are derived from the same
experiment and appear in this figure for completeness and clarity of results.

Six1 modulates macrophage migration inhibitory factor (MIF) in AT2 cells
I have presented data that supports the hypothesis that SIX1 is a novel
pathogenic transcription factor involved in the progression of fibrosis. We wanted to
further investigate how Six1 expression mechanistically functions in AT2 cells. Using
the MLE12 mouse AT2 cell line we performed RNA-sequencing on Six1 overexpressing
MLE12 cells (SixOE) compared to GFP control (Fig 16 A). I found that MIF expression
levels in SixOE were significantly increased compared to GFP controls (Fig 16 B).
These results suggest that MIF is a direct target of Six1 in AT2 cells. Six1 has been
shown to bind to the MEF3 consensus motif (CAGGTTTC) with strong affinity (kD
34.7 + 7.9 (10-9)) and is considered its canonical and most widely accepted binding
motif (99). In 2012, Liu et al. provided evidence that Six1 has a much more diverse
ability to bind to several iterations of this MEF3 motif and show that specific
nucleotide positions were critical for Six1 binding, including the suffix C (position 8),
while other positions (2,5,7) were able to change bases with similar binding kinetics
(100). I examined the promoter sequences of both mouse and human MIF genes and
found both of them to contain variations of the MEF3 motif with the critical C suffix
conserved throughout both mouse and human (Fig 16).
To further test if Six1 could modulate MIF levels and validate our RNA-seq, I
measured Six1 and MIF transcript levels by RT-qPCR that confirmed increased levels of
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Six1 and MIF in SixOE compared to contols (Fig 16 D,E). These results were consistent
with increased MIF protein levels in the SixOE cells (Fig 16 F).

Figure 16. Six1 modulates AT2 MIF expression in vitro. (A) Western blot showing
Six1 protein overexpression (Six1OE) compared to control MLE12 cells. (B) RNAsequencing data expressed as Log2 fold-change + SEM comparing GFP control MLE12 cells
(n=3) to SixOE (n=3); * p < 5.92E-14 (C) Representative picture depicting the MEF3 binding
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sites in the mouse and human MIF promoters. (D) RT-qPCR showing increased expression
of Six1 and (E) MIF in SixOE cells. (F) Western blot showing increase in Six1 and MIF
protein levels in SixOE cells compared to GFP controls. Data shown + s.d., unless specified.
* p < 0.01 using Mann-Whitney test.

I then wanted to examine if MIF expression was altered in vivo in our BLM mouse
model. Our data demonstrates that MIF is elevated following BLM-treatment in Six1competent mice and that deletion of Six1 prior to BLM-challenge results in a drastic
reduction of MIF mRNA levels (Fig 17 A). MIF is a secreted cytokine and as such we
analyzed the BALF of BLM-iAT2Six-/- mice compared to BLM-iAT2Cre, which demonstrates
reduced secreted MIF protein levels (Fig 17 B). I then examined whether Six1
overexpression using our SixTET and Spc-rtTA mice caused an increase in MIF. I
demonstrate that both MIF mRNA (Fig 17 C) and secreted MIF protein levels (Fig 17 D) are
increased in SixTET mice compared to Spc-rtTA mice treated with BLM.
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Figure 17. Six1 modulates AT2 MIF expression in vivo. (A) RT-qPCR showing increased
expression of MIF in PBS or BLM-treated mice with reduced expression in BLM-treated mice
following conditional Six1 deletion in AT2 cells prior to BLM exposure. Data shown + s.d. * p <
0.05 using One-way ANOVA with Holm-Sidak post hoc test (B) ELISA data of MIF protein
concentration expressed as ng/mL of MIF concentration in BALF of BLM-treated mice with
reduced concentration in BLM-treated mice following conditional Six1 deletion prior to BLM
exposure. (C) RT-qPCR showing increased MIF mRNA in SixTET mice compared to BLMtreated Spc-rtTA controls. (D) ELISA data of secreted MIF protein levels showing
increased concentration in SixTET mice compared to Spc-rtTA mice treated with BLM.
Data shown + s.d. * p < 0.05 using Mann-Whitney test.
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MIF promotes proliferation and differentiation of primary human lung fibroblasts.
In IPF, studies have shown an increase in MIF concentration in the BALF and
increased expression in lung tissue from IPF patients compared to control samples (146,
149). We thus demonstrate that MIF transcript levels are increased in IPF compared to
healthy patient samples (Fig 18 A). MIF has also been shown to effect the proliferation of
neighboring fibroblasts in cardiac tissues (145) and dermal fibroblasts(156), but how
secreted MIF affects lung fibroblasts remains poorly understood. We aimed to explore
how direct exposure to MIF protein in vitro affected primary human lung fibroblasts using
isolated fibroblasts from 4 independent healthy donors and exposing them to a known
concentration of recombinant human MIF (hMIF) for 24 hours. We show that human lung
fibroblasts treated with 100ng/mL of hMIF increased fibroblast cell proliferation as
measured by WST-1 proliferation assay (Fig 18 B). We then exposed fibroblasts to a dose
response (4-400ng/mL) of MIF in vitro for 48 hrs to assess for changes to fibroblast
differentiation using alpha-smooth muscle actin (aSMA) as a marker. We demonstrate no
significant change at the lower 4ng/mL exposure to MIF, but a significant increase from
baseline with both the 40 and 400 ng/mL as assessed by the integration of per cell
fluorescence pixel intensity using an automated fluorescence cell cytometer (Fig 18 C,D).
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Figure 18. MIF promotes proliferation and differentiation of primary human
lung fibroblasts. (A) MIF transcript levels in IPF (n=8) compared to control (n=8)
patient samples. (B) Absorbance values of WST-1 assay at 24 hrs read at 450nm for control
human lung fibroblasts (n=12 (4 donors in triplicate)) with or without 100ng/mL
recombinant human MIF. Data shown + s.d. *p < 0.05 using two-tailed, unpaired Student’s
t test with Welch’s correction. (C) Human lung fibroblasts treated with a dose response (4400ng/mL) of MIF in vitro for 48 hrs stained with alpha-smooth muscle actin (aSMA;
red signal). (D) Quantification of aSMA fluorescent signal using integration of per cell
fluorescence pixel intensity using an automated fluorescence cell cytometer. Data
shown + s.d. * p < 0.05 using One-way ANOVA with Holm-Sidak post hoc test.
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Discussion
AT2 cells are shown to have significant epithelial plasticity to allow for repair of
the injured alveolar space, and in IPF they have been shown to inappropriately express
developmental gene pathways (51, 70, 86). Despite this known re-activation of
developmental genes in lung fibrosis, there are only a few studies and pathways that
have been significantly interrogated. In this study I focused on the critical
developmental gene Six1 and its function in AT2 cells. Mechanistically, the absence of
Six1 in mice leads to severe epithelial branching abnormalities and pulmonary
hypoplasia, underscoring the vital role Six1 plays in normal lung development (90). In
contrast, various adult pathologies demonstrate inappropriately increased Six1
expression in adult tissues, including breast, esophageal, and lung cancers (110, 125,
157). Six1 is known to contribute to tumor formation and metastatic progression by
regulating multiple activities of cancer cells such as responsiveness to apoptotic
stimuli, cell proliferation, and epithelial differentiation, including through activation
of transforming growth factor (TGF)-β signaling (108, 116, 158-160). This activation
through TGF-β leads to an EMT phenotype in cancer with TGF-βR1 being a
demonstrated direct target of Six1 in breast cancer. Increased TGF-β signaling is well
studied in IPF with AT2 cell EMT (154) being reported as a potential contributor to IPF
progression, This highlights the importance of our results showing no change in TGFβR1 or other EMT markers and supports that Six1 acts in a cell specific context through
alternate mechanisms.
Additionally, we highlight the additional data that explores the role of cellular
senescence in the context of Six1 in lung fibrosis. Cellular senescence is a conserved
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state of replicative cellular arrest that is induced by various cell damage associated
factors including oxidative stress, DNA damage, and impaired proteostatis. Cellular
damage stimulates the activity of cyclin-dependent kinase inhibitors p16Ink4a (p16)
and p53-p21Cip1/Waf1 (p21) (161). In IPF, cellular senescence has been described in AT2
cells and fibroblasts as leading to reduced epithelial proliferation with an increase in
release of pro-fibrotic cytokines including IL-1, IL-6, IL-10, and TGF- β (162). Although
Six1 expression for 3 months in the AT2 cells and the addition of BLM-induced injury
did not significantly increase the levels of senescence markers in vivo, there was
increased DNA damage at 3 months which could suggest that chronic over-expression
of Six1 could lead to a premature aging of the lungs with increases in cellular
senescence.
In this study I propose a new gene target for Six1 and a novel regulator of MIF
in lung fibrosis. MIF is a conserved 12.5 kDa cytokine that has been shown to signal
through the binding of cell-surface receptors CXCR2, CXCR4, CD74, and CXCR7 (163165). MIF’s physiological role most recently as been described to promote cell
proliferation, migration and resistance to apoptosis, in addition to it’s previously
attributed pro-inflammatory role (145, 166, 167). In IPF, studies have shown an
increased in MIF concentration in the bronchoalveolar lavage fluid (BALF) and
increased expression in lung tissue from IPF patients compared to control samples.
Specifically, MIF expression in tissue was localized to the alveolar epithelium and
fibroblasts in areas of active fibrosis (146, 149). In addition, two studies have found
increased expression of MIF in lung tissue, BALF, and serum in BLM-treated mice
compared to untreated controls (168, 169). Interestingly, two recent studies showed
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MIF increases cardiac fibroblast proliferation and resistance to apoptosis (145, 150).
One study showed an increase in fibroblast production of collagen-1 and 3, MMP-2/9,
and TGF-β (145).
There has recently been increased interest in MIF as a potential therapeutic
target in chronic lung disease, including IPF. Recent work (144) highlights the current
developments in using MIF inhibitors in chronic inflammatory conditions, and in
chronic lung diseases like systemic sclerosis associated pulmonary hypertension (SScPH) and IPF. However, how MIF is regulated and how to effectively target MIF have
proven difficult. This is why I briefly describe the current research on MIF in lung
disease and highlight the importance of the findings of the proposed Six1/MIF axis
described in this current study.
There are currently 2 in vivo studies using a bleomycin mouse model of lung
fibrosis and a therapeutic MIF strategy (168, 169). The critical difference in these
studies was that Tanino, et al. treated mice with an anti-MIF antibody and
importantly showed decreased mortality, lung injury, and significantly lower
inflammation, but not collagen content at day 21. Günther, et al. treated mice with a
small molecule, cell-permeable MIF antagonist (ISO-1) that in addition showed
decreased fibrosis, collagen content, and decreased vascular smooth muscle
proliferation. This is an important difference as anti-MIF antibodies can target
secreted or systemic MIF without affecting MIF’s intracellular interaction with other
signaling molecules whereas non-protein based inhibitors have the potential to affect
both intracellular and secreted MIF pathways, both of which are still being actively
investigated in chronic lung disease(144).
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Importantly, this same concept has been shown in asthma studies. There have
been several studies using mouse or rat models of asthma that showed increase in MIF
with increased Th-2 cytokines and IgE levels, airway hyperresponsiveness, and airway
smooth muscle thickness (170-175). When two of these studies (171, 174) used anti-MIF
antibodies they observed decreased features of asthma, but did not see the decrease in
Th-2 cytokines and IgE levels, however when MIF was genetically deficient (175) or
when using a non-antibody MIF inhibitor like ISO-1 (170), the Th-2 cytokines and IgE
were significantly reduced. While only correlated and not directly studied, this thesis
also discusses two additional asthma studies showing similar effects of reduced
asthma phentoype in the same in vivo models while only targeting SIX1.
Interestingly, in lung cancer models, bleomycin-injured mice were used as a
source of increased MIF that promoted aggressive proliferation and reduced apoptosis
of the tumor (176, 177). This effect was not observed after lung injury in MIF-deficient
mice and MIF overexpression was sufficient to rescue this aggressive cancer
phenotype. Additional studies showed that miR-608 and miR-146a inhibition led to
increased MIF and more aggressive tumor phenotype, which was subsequently
decreased with MIF downregulation(178, 179).
While MIF’s current role in AT2 cells or in chronic lung disease is not
completely understood, these studies in lung fibrosis and other lung diseases provide
evidence that the role of MIF is complex and that intracellular regulation or targeting
of MIF can provide additional benefits than just anti-MIF antibodies and points
toward MIF’s role as a profibrotic mediator with a pathogenic role in lung fibrosis that
could be directly or indirectly affecting several aspects of the fibrotic process. This
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current study proposes a novel Six1-MIF signaling axis that could add to the current
knowledge of MIF in lung fibrosis and provides evidence that the intracellular
depletion of Six1 in AT2 cells reduces intracellular and secreted MIF in the lungs of
mice with bleomycin-induced lung fibrosis.
In summary, I demonstrate in this chapter that Six1 expression in the AT2 cells
exacerbates lung fibrosis in vivo and also proposed a novel mechanism whereby Six1
modulates MIF expression in AT2 cells that is important for the progression of lung
fibrosis. These findings propose Six1 as a novel regulator of MIF expression with the
Six1-MIF axis providing a potential therapeutic target in lung fibrosis. In the next
chapter, I explore this question of whether the Six1/MIF axis is a potential target by
testing the therapeutic capacity of Six1 depletion in vivo using our BLM mouse model
to deplete Six1 at two distinct time points after fibrosis has developed. Collectively,
these findings support a strong basis for the continued work on Six1 in the AT2 cells
with the potential to lead to many novel insights into the molecular mechanisms of
pulmonary fibrosis.

Chapter 5: Determining the therapeutic potential of targeting Six1 in
established pulmonary fibrosis.
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A portion of this chapter is based on data and figures that are currently under review.

Wilson, C, Mertens TCJ, Bi W, Collum SD, Wareing N, Ko J, Weng T, Naikawadi RP,
Wolters PJ, Maire P, Jyothula SK, Rajagopal K, Thandavarayan RA, Bruckner BA, Ren
D, Huang HJ, Dickey BF, Ford HL and Karmouty-Quintana H (2019). Sine Oculis
Homeobox Homolog 1 (Six1) Plays a Critical Role in the Progression of Pulmonary
Fibrosis. JCI Insight. (In review)

Rationale
IPF has been an extraordinarily difficult disease to target therapeutically.
Through the years of extensive research there exist only two FDA-approved
pharmacological treatments. This has sparked more research in IPF that is aimed at
furthering the current understanding of the underlying mechanisms of disease to gain
more insight into how to potentially target this disease. Current opinion on IPF
research is 2-fold and includes: 1) the identification of novel pathways or upstream
mediators that drive the progression of IPF and 2) more studies addressing the
preclinical assessment of anti-fibrotic capacity after the initial phase of inflammation
in animal models (180). This study addresses both the identification of a novel
transcription factor, Six1, and the use of a therapeutic model. Additionally, recent
work (144) also highlights the current developments and interest in using MIF
inhibitors in chronic inflammatory conditions, and in chronic lung diseases like
systemic sclerosis associated pulmonary hypertension (SSc-PH) and IPF. So far, I have
addressed the first point by proposing the developmental Six1 pathway as a novel
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pathway in IPF and that Six1 acts as a novel regulator of MIF expression with the Six1MIF axis providing a potential therapeutic target in lung fibrosis. In the context of this
chapter I will expand on the second point addressing the use of animal models and the
pre-clinical assessment of potential therapeutics in vivo.
When discussing preclinical IPF studies, it is important to address the animal
models that have been and are currently used in research as well as where the field is
going in terms of developing more unique models of lung fibrosis. The most widely
used and commonly accepted model of lung fibrosis is the use of the
chemotherapeutic drug bleomycin. Bleomycin (BLM) is a glycopeptide antibiotic that
is used in several cancers as a direct cytotoxic agent (55). In most organs, BLM is
metabolized by the cysteine protease bleomycin hydrolase, however in the lungs there
are very low levels leading to the accumulation of BLM and subsequent epithelial cell
damage leading to lung fibrosis development (181, 182). The most common delivery
method of BLM is directly to the lungs through instillation of the drug through a
single dose intratracheal administration. The controversy around this method is the
localization of the fibrosis in the lungs compared to human IPF, the reversibility, and
the highly inflammatory driven fibrosis. The last point is amplified as a concern
following the PANTHER-IPF trial that showed IPF was not responsive to antiinflammatory treatments, however this model has been shown to be rescued and
reversed using anti-inflammatory treatments (183). Nonetheless, the research field is
still widely using this model and a lot has been learned with this model about the
molecular mechanisms of lung fibrosis. Another model that uses BLM is the
multidose, systemic intraperitoneal (IP) delivery of BLM over the course of 33 days.
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The advantages of this model are the more consistent localization of fibrosis to the
distal, sub-pleural region, the much less prevalent reversibility, and less severe
inflammatory phenotype that shows physiological lung function changes consistent to
that of a chronic, restrictive lung disease (132).
More recently two unique models of lung fibrosis have been developed that are
designed to resemble the underlying genetic alterations associated with IPF
development. One model is a mutant SPC model using a mutated cysteine at codon 121
of SPC that causes improper folding, and AT2 cell injury through increased ER-stress
leading to spontaneous lung fibrosis (184). Another interesting model is the use of a
tamoxifen-induced deletion of the telomere shelterin protein TRF1 gene in AT2 cells.
Following 9 months of AT2 cell stress with rapidly shortening telomeres and increased
DNA damage, the mice develop spontaneous lung fibrosis with downstream features
that are associated with IPF including the increase in aSMA-expressing myofibroblasts
(67, 68). These models recapitulate the underlying genetics of what is known from
investigations of IPF and show promise for developing more specific, non-druginduced models that could more accurately represent the pathophysiology of IPF.
These evolving strategies that are being developed to study the preclinical
efficacy of potential treatments for IPF are important to advancing the field toward
more effective treatments. In this chapter I explore the potential of targeting Six1 in
vivo with a therapeutic approach using a conditional AT2 specific knock-out model. In
our therapeutic approach I utilized two different time points after fibrosis has been
established to reflect active fibrotic damage and chronic lung disease.
Results
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Conditional deletion of Six1 during active fibrosis halts progression
I have previously shown that Six1 is elevated in IPF and that conditional
deletion of Six1 prior to BLM protects mice from the development of lung fibrosis.
However, I have not demonstrated how deletion of Six1 affects the progression of lung
fibrosis during and after it is developed. In order to address this, I investigated
whether switching off Six1 during active fibrosis was able to halt fibrotic progression
and significantly improve lung function. In these experiments I treated iAT2Six-/- and
iAT2Cre mice with tamoxifen at day 15 after the initiation of BLM (Fig. 19 A). At this
time point, evidence of fibrosis is already present in this model that includes
alterations in lung function, fibrotic deposition and increased fibrotic gene expression
as previously described by the Karmouty lab (132). To confirm deletion of Six1 in these
experiments, I measured transcript levels in isolated AT2 cells from BLM-treated
iAT2Six-/- and iAT2Cre mice (Fig. 19 B). Surprisingly, I observed a significant reduction in
the histological burden of fibrosis (Fig. 19 C, D).
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Figure 19. Conditional deletion of Six1 during active fibrosis halts progression.
(A) Experimental BLM model with delayed treatment of tamoxifen. (B) RT-qPCR of Six1
from isolated AT2 cells from BLM-treated iAT2Six-/- and iAT2Cre mice. (C) Ashcroft scores.
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(D) Representative Masson's trichrome images low power field (LPF) and high power field
(HPF) (LPF scale bar 200um, HPF 100um). Data shown + s.d * p < 0.05 using MannWhitney test.

I also demonstrated a decrease in Col1a1, Col1a2, Col2a1 and Fn transcript expression
(Fig. 20 A-D). Consistent with the previous results proposing a novel Six1/MIF axis,
depletion of Six1 at day 15 resulted in significantly decreased gene expression of MIF in
the BLM-iAT2Six-/- compared to BLM-iAT2Cre mice (Fig. 20 E).
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Figure 20. Deletion of Six1 at day 15 of BLM treatment reduces fibrotic gene
expression and MIF. (185) RT-qPCR of fibrotic markers Col1A1, Col1A2, Col2A1, FN, and
(E) MIF from whole lung tissue. Data shown + SEM * p < 0.05 using Mann-Whitney test.
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These changes were consistent with in vivo lung function assessment that revealed
significantly improved whole respiratory elastance (Ers) and resistance (Rrs) (Fig. 21 A,
B) in BLM-iAT2Six-/- compared to BLM-iAT2Cre mice, reduced lower airway tissue
damping (G) and tissue elastance (H) (Fig. 21 C, D), and increased inspiratory capacity
(IC) and static compliance (Cst) (Fig. 21 E, F). Taken together, these results
demonstrate that deletion of Six1 during active injury is capable of halting the
progression of ongoing lung fibrosis.
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Figure 21. Deletion of Six1 at day 15 of BLM exposure improves in vivo lung
function. (A) Whole respiratory elastance (Ers) and (B) resistance (Rrs) measure using
the single frequency flexiVent forced oscillation perturbation under closed chest
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conditions. (C-D) Partitioned, broadband FOT showing tissue damping (G) and tissue
elastance (H). (E-G) Inspiratory capacity (IC) with static compliance (Cst) and pressurevolume (PV) curve (G) using a ramp-style pressure-driven (PVr-P) maneuver. (H)
Newtonian resistance (Rn) of central airways. Negative-pressure expiratory parameters
forced vital capacity (FVC; E) or forced expiratory volume (FEV0.1; F). Data shown +
s.d. * p < 0.05 using Mann-Whitney test.

Investigating the potential of Six1 as a therapeutic target after the development of
fibrosis using a conditional deletion model
In these experiments I treated iAT2Six-/- and iAT2Cre mice with tamoxifen at day
33 after the full course of BLM (Fig. 7 A) then measured their lung function and
collected tissue at day 57. The success of experimental therapeutics in animal models
of lung fibrosis often rely on the attenuation of histologic and molecular indices of
lung fibrosis (e.g., collagen content assays, histological scoring and fibrotic gene
expression). However in humans, disease progression in IPF patients is often
determined using imaging and lung function analyses (137), as such we performed
comprehensive lung function analyses, including both mechanical parameters as
previously discussed as well as functional lung volume spirometry, including
functional residual capacity (FVC) and the forced vital capacity in 0.1 seconds
(FEV0.1). Determining lung volumes is the current accepted gold-standard in human
clinical trials of lung disease and provides comparable clinical data about response
and efficacy of a treatment. Interestingly, there was an improvement of in vivo lung
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function assessment that revealed significantly improved whole respiratory elastance
(Ers) and resistance (Rrs) (Fig. 22 A, B) in BLM-iAT2Six-/- compared to BLM-iAT2Cre
mice, reduced lower airway tissue damping (G) and tissue elastance (H) (Fig. 22 C, D),
and increased inspiratory capacity (IC) and static compliance (Cst) (Fig. 22 E, F).
Additionally, there was significant improvement in the FVC and FEV0.1 BLM-iAT2Six-/compared to BLM-iAT2Cre mice (Fig 22 G,H). These results demonstrate that the
depletion of Six1 in the AT2 cells during chronic fibrosis can significantly improve the
physiological lung function in mice.
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Figure 22. Conditional Six1 deletion in AT2 cells at day 33 of BLM exposure
significantly improved lung function at day 57. (A) Whole respiratory elastance (Ers)
and (B) resistance (Rrs) measure using the single frequency flexiVent forced oscillation
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perturbation under closed chest conditions. (C-D) Partitioned, broadband FOT showing
tissue damping (G) and tissue elastance (H). (E-F) Inspiratory capacity (IC) with static
compliance (Cst) using a ramp-style pressure-driven (PVr-P) maneuver. Data shown + s.d.
* p < 0.005 using Mann-Whitney test.

Discussion
Assessing novel therapies for IPF is a daunting task. This disease is
multifactorial and potentially has many escape mechanisms and a highly variable
clinical course. The use of animal models has led to many new insights into fibrosis
development, but until recently, have not focused on the assessment of potential
therapies in a ‘therapeutic model’ in which genetic manipulation or administration of
drug compounds are administered during or after the development of fibrosis. A
recent analysis of the timing of intervention using the widely utilized bleomycin
model was conducted on 726 published studies assessing therapies from 2008-2019
showing that only 37.4% of studies used any type of non-preventive, therapeutic
animal model (186) . It is important to note that while the majority of these studies
still did not look at the therapeutic capacity, it is a major improvement from the
previous three decades of research. In 2008, Moeller et al. systematically reviewed all
the indexed publications from 1980-2008 using the bleomycin mouse model that
assessed a drug or candidate compound and found that only 10 of out 221 studies
(<5%) used a therapeutic model (183). Importantly, 2 of the 10 studies were assessing
the compounds pirfenidone and nintedanib (BIBF1000) that led to the current two
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drugs available for IPF, which highlights the necessity for using a therapeutic model in
preclinical IPF research. The translation of high-quality preclinical research is
necessary for the development of future therapeutics. This is emphasized by the fact
that of all 145 registered clinical trial for IPF investigating a therapy; only 26% have
supporting preclinical data using this animal model (186).
Collectively, this study provides evidence that suggests the Six1 pathway in AT2
cells could provide a novel therapeutic target for future development with the added
benefit that Six1 is not widely expressed in adult tissue, which could limit potential offtarget effects. One of the most challenging aspects of drug discovery for IPF is the
identification of new targets using preclinical animal models of lung fibrosis that can
be translated effectively (132), which is why I highlight the importance of our results
showing reduced progression of fibrosis and improved physiological lung function
using the therapeutic deletion of Six1. In addition, the development of novel
therapeutics that target transcription factors is challenging. However, recently the
crystal structure for the Six1/Eya2 complex was determined which showed that Six1
uses a single alpha helix to interact with Eya2 (159). This interaction is very similar to
the protein-protein interactions of p53/MDM2 (187) and Bak/Bcl-xl (188), which have
been successfully targeted with small molecule inhibitors.
In summary, IPF is an insidious, devastating disease with high mortality and
limited therapeutic options. I present the novel findings that Six1 and its cofactors Eya1
and Eya2 are increased in IPF and that both prophylactic and therapeutic deletion of
Six1 in a BLM model prevents or halts the progression of fibrosis. These findings
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support a strong basis for the continued work on whether targeting Six1 in the alveolar
epithelium could provide a potential therapy in pulmonary fibrosis.
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Chapter 6: Future Directions and Conclusion

Future Directions
Six1 represents a novel pathway in lung fibrosis in which we can investigate
further with many open questions remaining. How is Six1 regulated in the alveolar
epithelium; what are the additional gene targets of Six1 in the AT2 cells; and can Six1
be effectively targeted with small molecule inhibitors in vivo? These are a few
questions that I plan to address in the future studies of Six1 and I have outlined my
approach with the addition of some supportive preliminary data.

Six1 regulation in AT2 cells
There are very few studies that explore the regulation of Six1 expression in cellspecific contexts. In cancer studies looking at Six1 regulation there was a study that
showed that Six1 was increased in granulocyte-macrophage progenitor cells using a
mixed-lineage rearrangment leukemia model (MLL-AF9). It has also been shown that
in colorectal cancer that HIF-1a and hypoxia can drive Six1 expression (189, 190). I
looked at the latter as a potential source of Six1 regulation in lung fibrosis given the
hypoxic environment of the damaged alveoli. Using the MLE12 cell line, I exposed
them to a hypoxic environment (1% O2) for 24 hours and tested HIF-1a expression and
Six1 expression by western blot with an increase in both HIF-1a and Six1 expression
after 24 hours in hypoxia(Fig. 23 A). I then looked at several known growth factors
that are important in IPF and ran an expression screen using MLE12 cells and Six1
expression as a readout of Six1 regulation over a timecourse of 6, 12, and 24 hours. I
98

used serum starvation as a control, TGF-β, the WNT agonist CHIR, the Notch
antagonist DAPT, Mitomycin C (DNA damage agent), TNF-a, and Dexamethasone,
with CHIR and TGF-β being responsive and very relevant in this cell context (Fig. 23
B). To further investigate, I used the Six1-expressing human lung epithelial cell line
A549 and tested it further with TGF-β. It showed that 24 hour exposure to 10ng/ml of
TGF-β decreased Six1 expression compared to control, FGF2, and human epidermal
growth factor (hEGF) (Fig. 23 C). I wanted to then test whether the β-catenin increase
caused by the CHIR-mediated WNT activation could directly cause binding and
activation of the Six1 promoter. I used a Gaussia luciferase Six1 promoter plasmid
(pGLUC-Six1) and transfected MLE12 cells for 24 hours then stimulated with 6uM of
CHIR for 24 hours. There was no significant activation of the Six1 promoter as
measured by the quantification in luminescence (Fig. 23 D).
The regulation of Six1 is an important and elusive piece of information that is
not well studied and could add great value to the knowledge of the Six1 pathway in
lung fibrosis. Together, this project provides intriguing preliminary data for the future
study of Six1 regulation in AT2 cells in lung fibrosis and could provide the focus of a
future project.
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Figure 23. Potential regulators of Six1 in lung epithelial cells. (A) Mouse AT2
MLE12 cell line expose to hypoxic environment (1% O2) for 24 hours with HIF-1a and
Six1 expression measured by Western blot. (B) Western blot screen using MLE12 cells

100

and Six1 expression as a readout of Six1 regulation over a timecourse of 6, 12, and 24
hours (in order from left to right) using serum starvation as a control (1), the WNT
agonist CHIR(153), the Notch antagonist DAPT(3), Mitomycin C (DNA damage agent;
4), TNF-a(5), Dexamethasone(6), and TGF-β (7). (C) Human epithelial A549 cell line
exposed to 24 hour of 10ng/ml of TGF-β showing decreased Six1 expression compared
to control (C; lane 1), FGF2, and human epidermal growth factor (hEGF). (D) Gaussia
luciferase Six1 promoter plasmid (pGLUC-Six1) transfected in MLE12 cells for 24 hours
then stimulated with 6uM of CHIR for 24 hours. Data with n.s denotes no significant
difference using 2-way analysis of variance (ANOVA) test.

Six1 as a therapeutic target in fibrosis
Overall, there are approximately 8 known Six1 mutations that lead to BOR
syndrome, but only 6 have been functionally characterized. Of the 6 wellcharacterized mutants, the only mutant to disrupt protein-protein interactions with
the Eya proteins is Six1 V17E, which resides in the Six domain (SD) region (191). This
provides two mechanisms that can potentially disrupt Six1 ability to activate
transcriptional programs during development by either disrupting the DNA
recognition residues in the homeodomain or through abolishing protein-protein
interactions with Six1 co-factors. The analysis of these mutations shows that the
disruption of the protein-protein interactions of Six1 and its cofactors could provide a
therapeutic avenue for Six1 inhibition. The development of novel therapeutics that
target transcription factors is challenging. However, recently the crystal structure for
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the Six1/Eya2 complex was determined which showed that Six1 uses a single alpha
helix to interact with Eya2 (159). This interaction is very similar to the protein-protein
interactions of p53/MDM2 (187) and Bak/Bcl-xl (188), which have been successfully
targeted with small molecule inhibitors.
Fibrotic lung diseases, particularly IPF, have been extraordinarily difficult
diseases to target therapeutically. Through the years of extensive IPF research there
exist only two FDA-approved pharmacological treatments. This has sparked more
research in IPF that is aimed at furthering the current understanding of the
underlying mechanisms of disease to gain more insight into how to potentially target
this disease. Currently the focus of IPF research includes the identification of novel
pathways or upstream mediators that drive the progression of IPF and the need for
more studies addressing the preclinical assessment of anti-fibrotic capacity after the
initial phase of inflammation in animal models (180). Six1 provides a unique target
compared to other transcription factors. The lack of or extremely low baseline Six1
expression in almost every adult tissue suggests that the therapeutic silencing of Six1
in disease could limit potential off-target effects. This thesis expands upon these ideas
that Six1 could be a novel therapeutic target in fibrotic lung disease by addressing the
first point above through the identification of the novel transcription factor, Six1, and
the second point above with the use of therapeutic animal model of lung fibrosis
showing that Six1 depletion during and after fibrosis development slowed the
progression of lung fibrosis.
I plan on continuing assessing the therapeutic capacity of targeting Six1 in vivo
using a recently published small molecule inhibitor that is specific to the Six1 and Eya2
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interaction (192). This could provide two important and novel concepts: 1) is Eya2
responsible for Six1 transcriptional acitvity in AT2 cells and 2) can targeting the
Six1/Eya2 complex improve lung fibrosis in vivo. While it is known that Six1 and Eya2
are increased in lung fibrosis and are well known co-activators, whether Eya2 is the
main co-activator is not known. The use of this inhibitor could help assess whether
Eya2 is the main or solely responsible co-activator of Six1 in AT2 cells.

Six1 in AT2 cell proliferation
There has been debate recently about whether AT2 cell senescence or AT2
hyperplasia are the driving forces in fibrosis development. Various reports of IPF
histology have included the accumulation of hyperplastic AT2 cells suggesting that
increased AT2 cell proliferation could be responsible for the impaired epithelial
phenotype seen in IPF. I have preliminary data that is aimed at answering whether
Six1 increased AT2 cell proliferation, however more investigation is required to fully
understand how Six1 affects AT2 cell proliferation. I used MLE12 cells overexpressing
Six1 (Six1OE) compared to GFP-expressing controls as well as Six1-siRNA (siRNA)
treated cells and cells with both Six1 and Eya2 (Six1+Eya2). Surprisingly, SixOE and
Six1+Eya2 did not show significant changes in cell proliferation as measured using the
WST-1 assay (Fig 24 A). Six1OE also did not show significant change in the
quantification of phosphorylated histone H3 at serine 10 (pHH3) compared to the GFP
control (Fig 24 B,C) as a measure of cell proliferation. Interestingly, the siRNA treated
cells showed a significant increase in both WST-1 and pHH3 assays suggesting higher
active cell division and proliferation compared to Six1OE (Fig 24 A-C). These results
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were surprising and opposite to all of the cancer related studies of Six1, therefore I will
focus on using additional studies and in vitro and in vivo methods to carefully and
explicitly assess how Six1 affects AT2 cell proliferation.
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Figure 24. MLE12 Six1 depletion increases proliferation in vitro. (A) WST-1 assay
using MLE12 cells overexpressing Six1 (Six1), Six1 and Eya2 (Six1/Eya2) and Six1-siRNA
(siRNA) compared to GFP-expressing controls. (B) Representative images (scale bars
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in white, 100um) of pHH3 staining (green signal) in MLE12 cells with either Six1
overexpression (Six1) and Six1 siRNA (siRNA) treated cells for 48 hrs with
quantification of phosphorylated histone H3 at serine 10 (pHH3). All samples were
counterstained with DAPI (blue signal). (C) Comparing positive pHH3 signal per DAPI
signal using an automated fluorescence cell cytometer. Data shown + s.d. * p < 0.05
using One-way ANOVA with Holm-Sidak post hoc test.

Additional Six1 target genes
Transcription factors (193) can be highly cell-specific and context dependent
which leads to the need to characterize them in multiple cell contexts. Downstream
gene targets of Six1 have not been studied previously in the setting of either
pulmonary fibrosis or AT2 cells. In this study I have identified the downstream Six1
target MIF. I have preliminary data to show that the profibrotic mediator connective
tissue growth factor (CTGF) was increased with Six1 overexpression in AT2 cells and
partially reversed using a Six1-Eya2 specific inhibitor. The potential to identify several
known and novel profibrotic gene targets through further Six1 research is immense.
The characterization of all possible gene targets of Six1 in AT2 cells has not previously
been described and presents an additional source of scientific inquiry for future
investigation.
I propose a method by which to describe the downstream gene targets of SIX1
in AT2 cells through chromatin profiling using the recently validated cleavage under
targets and release using nuclease (CUT&RUN) (194-198). This technique is an
epigenetic profiling tool using an enzyme-tethering technique that utilizes non-fixed
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cells followed by in situ binding of a target-specific antibody with a protein Amicrococcal nuclease fusion protein (pA-MN) that allows for higher specificity using
significantly less cells with an optimized signal-to-noise ratio compared to traditional
ChIP-Seq methods (199). Using human and mouse Six1 overexpressing AT2 cells, I will
profile the gene targets of Six1 with CUT&RUN followed by paired-end sequencing
using the Illumina HiSeq 3000 platform. I will analyze the results using the optimized
Sparse Enrichment Analysis for CUT&RUN (SEACR) peak-calling algorithm, which
enforces stringent background optimization with high thresholds necessary for
accurate peak identification (195, 196). Additionally, I will validate the results using the
readily accepted, model-based analysis for ChIP-Seq (MACS2) to predict binding sites
and motif analysis using the differential motif discovery algorithms software HOMER
(195). These data will be used to show how Six1 regulates the genes associated with
epithelial differentiation and proliferation in AT2 cells and give detailed insight into
additional target genes for future study. These experiments will identify the direct
downstream targets of Six1 in AT2 cells in lung fibrosis.

Conclusion
This thesis demonstrated that there is increased Six1 transcript and protein
expression in IPF compared to healthy controls and that conditional deletion or
overexpression of Six1 in AT2 cells in mice can significantly halt or worsen
development of lung fibrosis, respectively. It also proposes a novel mechanism
whereby Six1 modulates MIF expression in AT2 cells that is important for the
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progression of lung fibrosis. The completion of this project helped advance the
mechanistic understanding of pulmonary fibrosis by identifying a unique role for the
transcription factor Six1. Understanding the mechanisms by which Six1 acts on the
AT2 cells will be key to the development of novel therapeutic targets and the
advancement of the current scientific understanding of the progression of pulmonary
fibrosis and provides unique opportunities on which to build future research.
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Table 1 Human lung donor characteristics. Data is shown as mean ± SEM. BMI,
body mass index; FEV1, forced expiration volume over 1 second; FVC, forced vital
capacity; IPF, idiopathic pulmonary fibrosis, COPD, chronic obstructive pulmonary
disease.
CONTROL

COPD

IPF

AGE (years)

42 ± 20.4

64.4 + 6.0

66.4 ± 1.9

GENDER

4/7

10/8

7/14

HEIGHT (cm)

164.4 ± 37.2

170.6 + 10.6

170.8 ± 10.7

WEIGHT

78.2 ± 20.3

74.2 + 16.2

83.4 ± 16.0

BMI

26.5 ± 6.2

24.5 + 5.5

29.0 ± 6.0

FVC (%)

-

52.4 + 11.5

48.6 ± 17.6

FEV1 (%)

-

23.9 + 8.4

51.7 ± 19.5

(female/male)

Table 2. Primary and Secondary Antibodies
Antibody Source
SIX1
mouse

Target
mo

Catalog
1593

Dilution
1:1000
(WB)

hu,mo,rat

Provider
Gift from
Dr. Heide
Ford
abcam

aSMA

rabbit

ab5694

rabbit

hu,mo

Sigma

HPA003868

SIX1

rabbit

hu,mo,rat

CST

12891S

ß-actin

rabbit

hu,mo,rat

CST

4967S

SIX1

rabbit

hu,mo

Sigma

HPA001893

1:1000
(IHC)
1:1000
(WB/IF)
1:100
(IHC/IF)
1:3000
(WB)
1:100

MIF
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EYA1

mouse

hu

Aldrich
Abnova

EYA2

rabbit

hu

Abcam

SPC

rabbit

hu,mo,rat

Millipore

EYA2

rabbit

hu,mo

Alexa
Fluor 488
Alexa
Fluor 594
Alexa
Fluor 488
Alexa
Fluor 633
Alexa
Fluor 594
Alexa
Fluor 488

rabbit

mouse

goat

rabbit

goat

rabbit

goat

mouse

donkey

goat

donkey

rabbit

Thermo
Scientific
Thermo
Scientific
Thermo
Scientific
Thermo
Scientific
Thermo
Scientific
Thermo
Scientific
Thermo
Scientific

(IF)
H00002138- 1:1000
A01
(WB)
ab92505
1:3000
(WB)
Ab3786
1:200
(IHC)
1:1000
(IF)
PA5-68561 1:10,000
(WB)
A11059
1:1000
(IF)
A11012
1:1000
(IF)
A11008
1:1000
(IF)
A21052
1:1000
(IF)
R37119
1:500
(IF)
R37114
1:500
(IF)

Table 3. Human and Mouse Primers
Gene
GAPDH
GAPDH
18S
18S
EYA2
EYA2
EYA4
EYA4
EYA1
EYA1
FN1
FN1
SIX1
SIX1
SIX2
SIX2
SHH

Primer name
GAPDH_homo_FW
GAPDH_homo_RV
18S_homo_mus_FW
18S_homo_mus_RV
EYA2_homo_FW
EYA2_homo_RV
EYA4_homo_FW
EYA4_homo_RV
EYA1_homo_FW
EYA1_homo_RV
FN1_homo_FW
FN1_homo_RV
SIX1_homo_FW
SIX1_homo_RV
SIX2_homo_FW
SIX2_homo_RV
SHH_homo_FW
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Sequence 5’ – 3’
AAGGTGAAGGTCGGAGTCAAC
GGGGTCATTGATGGCAACAATA
GTAACCCGTTGAACCCCATT
CCATCCAATCGGTAGTAGCG
CTACCAGATGCACGGCACAA
AGCCGGGGTAGGAAGGATAG
TCTGATTCTGTGCACGTTTTCT
CTACTTGGGAGTGGCAGGAG
TCCATGACTCCCAATGGCAC
GGGTATGGTCTGTTGGAAGGG
GGTGGAATAGAGCTCCCAGG
GCAGCCTGCATCTGAGTACA
CTGCCGTCGTTTGGCTTTAC
GCTCTCGTTCTTGTGCAGGT
CGGGTTGTGGCTGTTAGAAT
CACCACACAGGTCAGCAACT
CCAAAGCGTTCAACTTGTCC

SHH
SIX4
SIX4
SIX6
SIX6
SP-C
SP-C
MIF
MIF
Col1A1
Col1A1
Col1A2
Col1A2
Six1
Six1
CrebBP
CrebBP
Dach1
Dach1
18S
18S
Eya2
Eya2
Eya4
Eya4
Eya3
Eya3
Fn1
Fn1
Shh
Shh
Six4
Six4
Sftpc
Sftpc
Smo
Smo
Gli1
Gli1
Gli2
Gli2
MIF
MIF
MMP11
MMP11
CD74

SHH_homo_RV
SIX4_homo_FW
SIX4_homo_RV
SIX6_homo_FW
SIX6_homo_RV
SP-C_homo_FW
SP-C_homo_RV
MIF_homo_FW
MIF_homo_RV
Col1A1_mus_F2
Col1A1_mus_R2
Col1A2_mus_F1
Col1A2_mus_R1
Six1_mus_FW
Six1_mus_RV
CrebBP_mus_F2
CrebBP_mus_R2
Dach1_mus_F1
Dach1_mus_R1
18S_homo_mus_FW
18S_homo_mus_RV
Eya2_mus_F1
Eya2_mus_R1
Eya2_mus_F3
Eya2_mus_R3
Eya3_mus_F1
Eya3_mus_R1
Fn1_mus_F1
Fn1_mus_R1
Shh_mus_F1
Shh_mus_R1
Six4_mus_F2
Six4_mus_R2
Sftpc_mus_F1
Sftpc_mus_R1
Smo_mus_F1
Smo_mus_R1
Gli1_mus_F1
Gli1_mus_R1
Gli2_mus_F1
Gli2_mus_R1
MIF 1_ Mus_F1
MIF 1_ Mus_R1
MMP11_ Mus_F1
MMP11_ Mus_R1
CD74_ Mus_F1
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TTTAAGGAACTCACCCCCAA
GGGAGCAAGAGAGCTCAAGA
GTCAGTGGCAGCTTCACAAG
CTGTGACAGGACCTGCTGC
CAACCGGACTGACCCCTAC
CGATAAGAAGGCGTTTCAGG
AGCAAAGAGGTCCTGATGGA
GAACAACTCCACCTTCGCCT
CCGTTTATTTCTCCCCACCA
GGTTTCCACGTCTCACCATT
CGGCTCCTGCTCCTCTTAG
AGCAGGTCCTTGGAAACCTT
AAGGAGTTTCATCTGGCCCT
GAAAGGGAGAACACCGAAAACA
GTGGCCCATATTGCTCTGGA
ACAAGCGAAACCAACAAACCAT
CGTCTGAGGCTGGTTCATGT
CTTAGGAGGCCTTCCAGGTC
GAACCGCTGCAAACTCATCT
GTAACCCGTTGAACCCCATT
CCATCCAATCGGTAGTAGCG
GATAATCCTGGTGCACGCTC
CAGAGCCCCTACACCTACCC
AACCCAGCTGATTCCTGCTC
GGCATGTTGTGCTGGTTAGC
GGACTGAATTGCAGGTCTCTG
GTTCCAGAGTGGGTCCGTAA
ACTGGATGGGGTGGGAAT
GGAGTGGCACTGTCAACCTC
GGCCAAGGCATTTAACTTGT
CCAATTACAACCCCGACATC
CTGTGGCTGGCTCACTTGTA
GGAGCATTGGATTCTCTCCA
ATGAGAAGGCGTTTGAGGTG
AGCAAAGAGGTCCTGATGGA
GAGCGTAGCTTCCGGGACTA
CTGGGCCGATTCTTGATCTCA
CCAAGCCAACTTTATGTCAGGG
AGCCCGCTTCTTTGTTAATTTGA
CAACGCCTACTCTCCCAGAC
GAGCCTTGATGTACTGTACCAC
GCCAGAGGGGTTTCTGTCG
GTTCGTGCCGCTAAAAGTCA
CCGGAGAGTCACCGTCATC
GCAGGACTAGGGACCCAATG
AGTGCGACGAGAACGGTAAC

CD74
CXCR4
CXCR4

CD74_ Mus_R1
CXCR4_ Mus_F1
CXCR4_ Mus_R1
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CGTTGGGGAACACACACCA
GAAGTGGGGTCTGGAGACTAT
TTGCCGACTATGCCAGTCAAG

Methods
The following described methods have been adapted from our labs previously
published work (below copyright) and some appear exactly as previously published due
to specific protocols and reagents used in our laboratory. All other adaptations of
previously described protocols are as referenced.
•

Collum SD, Chen NY, Hernandez AM, Hanmandlu A, Sweeney H, Mertens TCJ,
Weng T, Luo F, Molina JG, Davies J, Horan IP, Morrell NW, Amione-Guerra J, AlJabbari O, Youker K, Sun W, Rajadas J, Bollyky PL, Akkanti BH, Jyothula S, Sinha
N, Guha A, Karmouty-Quintana H. Inhibition of hyaluronan synthesis attenuates
pulmonary hypertension associated with lung fibrosis. Br J Pharmacol 2017
o

Copyrights for the written article remain with the authors, but the Wiley
Publishing Group via the British Pharmacological Society has been granted
the exclusive license for use of the article

Human subjects
The courageous donation of lung tissue for the advancement of science deserves
adequate recognition. I could not have completed this project without the
sacrifice of the patients involved and for that I am greatly appreciative. Thank
you to those patients and their families for their sacrifice.
The use of human material for this study was reviewed by the University of Texas
Health Science Center at Houston Committee for the Protection of Human Subjects
(Institutional Review Board no. HSC‐MS‐08‐0354). The demographic details of the
study population are summarized in Table 1. De‐identified lung explant tissue from
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patients with IPF and COPD with corresponding de‐identified clinical parameters
were obtained from the Methodist Hospital (Houston, TX). IPF or COPD was
diagnosed

by

board‐certified

pulmonologists

upon

admittance

for

lung

transplantation at the Houston Methodist Hospital. Control lung tissue was obtained
from lungs that were declined for transplantation but had no pulmonary chronic
disease or contusion. Healthy control lung tissue was obtained from the International
Institute for the Advancement of Medicine (Edison, NJ).
Tissue was collected at the time of lung explantation and processed on site
within 20 min. The lobes were identified from each lung explant, and for each lobe,
the center was identified using a large central airway (transverse diameter > 10mm) as
a reference point. A 1 cm transverse center cut was performed to obtain a section from
the center of each lobe. Consequently, this tissue was divided into three sections to
separate external (closest to pleura), center and internal (closest to bronchi) portion
according to the airway. A piece from each portion was then cut for histology, and an
adjacent section was flash frozen in liquid nitrogen.

Animals
All studies were reviewed and approved by The University of Texas Health Science
Center at Houston Animal Welfare Committee (AWC-16-0060/ AWC-19-0029). Mice
generated for this study included the development of an alveolar type II-specific
conditional

knockout

mouse

(iAT2Six-/-)

using

the

tamoxifen-inducible

Cre

recombinase (Cre-ERT2) under the control of the human surfactant protein C (SPC)
promoter as previously described (Gui, et al, 2012). Six1-Flox/Flox mice were a gift
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from Pascal Maire, Inserm U1016, Institut Cochin. 75014 Paris, France. Additional mice
generated included the doxycycline-inducible AT2 Six1 over-expressing SixTET mice
using Six1Tet mice consisting of a human Six1 construct downstream of tet operator
sequences (as described,(152)) with the surfactant protein C (SFTPC) reverse
tetracycline

transcriptional

activator

(rtTA)

driver

(Jackson,B6.Cg-Tg(SFTPC-

rtTA)5Jaw/J; 006235). To induce fibrosis, mice were administered 0.035U/g I.P. of BLM
(Hospira Pharmaceuticals, Lake Forest, IL, USA) or vehicle (PBS; Invitrogen, Carlsbad,
CA, USA) twice a week for 4 weeks as previously described (132). All mice used for this
study were 6-8 week old males weighing approximately 21-23g. Animal care was in
accordance with institutional and National Institutes of Health guidelines. Animals
were randomized into treatment groups by cage, with all littermates receiving either
PBS (vehicle control) or BLM. Sample sizes were selected based on a power analysis
identifying the minimal number required to conduct statistical analysis.

Justification of Animal Models
Our lab is aware of difficulties in modelling human fibrotic lung diseases, like
IPF. While the bleomycin-induced model of fibrosis utilized in this proposal is
considered an accepted model, it does not reproduce all pathological features of
human disease. However, there is much we can learn about the mechanisms of lung
fibrosis, as well as essential pre-clinical data using mouse models. Our model consists
of 8 intraperitoneal (IP) injections of bleomycin (BLM) (0.035U/g) over the course of
33 days. Due to the predominance of fibrotic disease in older males and the persistent
and reproducible fibrotic response of IP BLM-induced injury in male mice, we will
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utilize male mice using the IP BLM model for all initial studies. Additional female
mice will be used to confirm key findings. Our lab has extensive experience using this
model and prefers it due to the persistent fibrotic response and reproducibility. Mice
used in this project consist of complete and cell-specific gene knockout and overexpressing animals that have been generated by our lab (Six1f/f SpcCre-ERT2;
Six1TetOSpcrtTA). Control mice will include SpcCre-ERT2, SpcrtTA and C57BL/6.

Bleomycin
Mice were treated with 0.035 U/g−1 of bleomycin (TEVA Pharmaceuticals, Sellersville,
PA, USA) or vehicle (PBS; Life Technologies, Grand Island, NY) twice a week for 4
weeks I.P. On day 33, physiological readouts were performed and the animals were
then sacrificed for the collection of tissues and fluids for analysis. Mice were assessed
bi‐weekly for changes in body weight, lack of grooming or hunched posture by lab
personnel and once‐weekly by veterinarians at our facility.

RT‐PCR
Total RNA was isolated from frozen lung tissue using Trizol reagent (Life
Technologies). RNA samples were then DNase treated (ArticZymes, Norway) and
subjected to quantitative real‐time RT‐PCR. Here two technical replicates were
performed per sample. Prior to RT‐PCR experiments RNA quality was evaluated using
a Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA); to evaluate 260 nm / 280
nm absorbance values. Samples with 260/280 absorbance ratios below 1.90 or above
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2.10 were considered to have poor RNA quality and thus violated a predetermined
criterion.

Immunoblots
For immunoblots, protein from lung tissue lysates or AT2 cells were extracted with
RIPA buffer (Thermo Scientific, Rockford, IL) containing 1 mM of protease and
phosphatase inhibitor (Sigma Aldrich). Samples (20 μg protein each) were loaded onto
4–12% Mini‐Protean TGX gels (Bio‐Rad, Hercules, CA) for electrophoresis and then
transferred on polyvinylidene difluoride (PVDF) membranes (0.45 μm, GE Healthcare
Piscataway, NJ). Membranes were then blocked in 5% Bovine serum albumin (BSA)
(Bio‐Rad) for 1 h at room temperature and then incubated with the appropriate
primary antibody overnight in 5% BSA. HRP-conjugated secondary antibodies and an
ECL kit from (GE Healthcare) were applied for generating chemiluminescent signals.
Blots imaged with the ChemiDoc Touch (Bio‐Rad) using optimal auto exposure
settings. Quantification of these blots were analyzed with the Image Lab Software
(Bio‐Rad) to quantify densitometry as well as intensity of target bands and control
bands. The expression was then calculated relative to control band and output in
arbitrary units.

Cell Culture and Plasmids
The mouse alveolar type II cell line MLE12 (201) was used to assess Six1 function in
vitro. Cells were cultured using DMEM/F12 (Gibco™ 12634010) with 2% FBS
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supplemented with 0.005mg/ml insulin, .01mg/ml transfererrin, 30nM sodium selenite
(Corning® ITS 354350), 10nM hydrocortisone, 10mM β-estradiol, 10mM HEPES buffer,
and 2mM L-glutamine (HITES). Plasmids used include Six1-pcDNA3.1 and Flag-Eya2pcDNA3.1 (addgene, #49264). The generation of the Six1-pcDNA3.1 plasmid included
the subcloning of the full-length human or mouse Six1 insert (gift from Dr. Heide
Ford) into the pcDNA3.1 backbone using the Xhou1 and EcoR1 restriction sites.

Histology and immunohistochemistry (IHC)
On day 33, mice were weighed and anaesthetized with Avertin (500 mg/kg). Avertin
was prepared in house with a mixture of tert-amyl alcohol (EMD Millipore
corporation, Billerica, MA, USA) and 2,2,2 tribromoethanol (Sigma-Aldrich, St
Louis, MO, USA). When the mice were sufficiently anaesthetized and immediately
following lung function analysis, the neck was cervically dislocated and the lungs were
inflated with 10% phosphate-buffered formalin at 25 cmH2Oand fixed at 4◦C
overnight. Lungs were dehydrated in ethanol gradients and embedded in paraffin
(FFPE). Lung sections 4-5 microns thick, were deparaffinized using histoclear
(National Diagnostics, Atlanta, GA) and re‐hydrated through a decreasing ethanol
gradient ending in Tris-phosphate buffered saline (TBST; Sigma Aldrich). Sections
were then subject to high temperature antigen retrieval using a citrate buffer for 30
mins at 95 C, endogenous peroxidase and alkaline phosphatase were inactivated using
BLOXALL (Vector Labs, Burlingame, CA) and 2.5% normal horse or goat serum
(Vector Labs) were used as blocking solutions prior to incubation with the primary
antibody. Following overnight incubation with the primary antibody, sections were
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treated with the ImmPRESS polymer detection kits for alkaline phosphatase (Vector
Labs) based on the host of the primary antibody and developed using Vector red or
Vector Blue (Vector Labs). Lungs stained with Massons's Tri‐chrome were analyzed
using a modified Ashcroft scale optimized for mouse lung sections. For
immunofluorescence, sections were incubated with SMA and incubated with Alexa
Fluor 488 or Alexa Fluor 555 (1:500, Sigma-Aldrich, St Louis, MO) sections were
counterstained and mounted with DAPI or PI mounting media (Sigma-Aldrich, St
Louis, MO).

RNA-seq
MLE12 cells were transfected with either Six1-pcDNA3.1, Flag-Eya2-pcDNA3.1 or both
using jetPRIME manufactures protocol (Polyplus, France). Cells were collected and
lysed using TRIzol (Life Technologies) and total RNA purified using the RNeasy Kit
(QIAGEN). Total RNA-seq was performed with MiSeq(LC Sciences). RNA-seq reads
were aligned to the mouse genome (GRCm38, mm10) using Gencode VM23.

RNA-in situ hybridization

The following protocol was designed using the validated hybridization probes that
target the following sequences: Mouse SIX1 (1932-2819 of NM_009189.3), Human
SIX1 (799 - 2177 of NM_005982.3). We followed Advanced Cell Diagnostics (ACD)
manufacturers protocol for RNA-ISH (RNAscope®, ACD). Briefly, slides were
deparafinized through xylene and 100% ethyl alcohol, and quenched with
hydrogen peroxide for 10 minutes at room temperature. Slides were then washed
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in distilled water and placed in slow boiling Target Retrieval Reagent (RNAscope®
Target Retrieval, ACD) for 15 minutes. Slides were incubated with protease
treatment (RNAscope® Protease Plus, ACD) for 30 minutes in humidifying oven
at 40 C. After protease treatment, slides were washed in distilled water
and incubated with RNAScope probe for 2 hours in 40C humidifying
oven. Between each incubation step, slides were washed in wash buffer
(RNAscope® Wash Buffer, ACD) twice for 2 minutes each with agitation. Slides
were probed with AMPs 1-6 (ACD) as per manufacturer instructions. Detection
reagents (RNAscope® 2.5 Detection Kit RED, ACD) were added for 10 minutes, and
counterstained with hematoxylin. Slides were cleared in xylene and immediately
mounted with non-aqueous sealant (CytoSeal, Thermo Scientific).

Isolation of Human Alveolar Type II (AT2) Cells
The use of human material was reviewed by the UTHSC Committee for the Protection
of Human Subjects (HSC-MS-08-0354). The demographic details of the study
population are summarized in Table 1. Isolation of primary human AT2 cells was
adapted from a previously described protocol (202) with modifications. Tissue from
healthy and IPF lungs was collected from anatomically comparable regions. After
tissue perfusion, lung tissue was minced, followed by digestion in 0.25% Trypsin
(Sigma, St. Louis, MO). The tissue suspension was filtered through large mesh
followed by 100µm and 40µm cell strainers (Fisher Scientific, Waltham, MA). The
obtained cell solution was incubated in DMEM/F12 to remove macrophages and
fibroblasts. The remaining cell solution was separated on a Percoll (Sigma, St. Louis,
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MO) gradient as described (202). The obtained cells were lysed for subsequent analysis
or plated for AT2 marker evaluation.

Isolation of Murine Alveolar Type II (AT2) Cells
We use a modified protocol of Corti et al from Tulane Univ Med Center (Amer J of Resp
Cell and Mol Biol, 14, p310-315, 1996).
Murine AT2 cells were isolated by dispersion of lungs with Dispase and negative
selection with antibodies against CD32/16 and CD45 followed by lamellar bodies
staining with Lysotracker DND-26 (Cell Signaling Technologies (CST) Danvers, MA,
USA) and pro-surfactant protein-C (pro-SP-C) polyclonal antibody (Millipore
Corporation, Billerica, MA, USA) to stain surfactant protein-C.

Lung Function Assessment
Lung function measurements were performed using the flexiVent FX system (SCIREQ
Inc., Montreal QC, Canada). This system was equipped with the FX1 module and
operated by the Flexiware v8.3 software. Baseline ventilation was performed using
constant-volume ventilation at a tidal volume of 10 mL/kg, frequency of 150 breaths
per minute, and a positive end expiratory pressure (PEEP) of 3 cmH2O. On day 33,
mice were anesthetized with IP injection of 5% Avertin (0.012 ml/g body weight).
Once a surgical plane of anesthesia was reached, a tracheostomy was performed and
the trachea cannulated with an 18-gauge metal cannula with a resistance of
approximately 0.2-0.3 cmH2O.s/mL.
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After 1 minute of ventilation, the lungs were inflated to 30 cmH2O over 6 seconds
(Deep Inflation) to determine inspiratory capacity (IC) and returned to normal
ventilation for 1 minute. Respiratory mechanics were measured under closed chest
conditions by applying a forced oscillatory pressure (138) to the lungs and measuring
flow responses to the applied pressures. The single compartment mechanics (2.5 Hz;
SnapShot-150) oscillation was used to obtain respiratory system resistance (Rrs),
dynamic compliance (Crs), and elastance (Ers) and broadband (1–20.5 Hz; Quick
Prime-3) was used to measure Newtonian airway resistance (Rn), tissue damping (G),
and tissue elastance (H). This was followed by the generation of a pressure-volume
(PV) curve using a ramp-style pressure-driven (PVr-P) maneuver to a maximum of 30
cmH20 to calculate static compliance (Cst).

Statistical Analyses
Prism software (v6.0; GraphPad) was used for all statistical analyses. Student’s t-test or
Mann Whitney test was used to compare any paired conditions. One-way analysis of
variance (ANOVA) test followed by Holm-Sidak’s multiple comparisons post-test was
used when multiple conditions were being compared. Power analysis was conducted
to determine that an n = 6 will be necessary for the in vivo studies.

Following

consultation with a statistician, our experimental N number was set to 6 based on a
power analysis (F-tests ANOVA:One Way) with the following criteria: alpha error:
0.05, Power: 0.999, number of groups 4, f:1.2.
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